<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 14 (filtered)">
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:inherit;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:0in;
	line-height:115%;
	font-size:11.0pt;
	font-family:"Calibri","sans-serif";}
h1
	{mso-style-link:"Heading 1 Char";
	margin-right:0in;
	margin-left:0in;
	font-size:24.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
h2
	{mso-style-link:"Heading 2 Char";
	margin-right:0in;
	margin-left:0in;
	font-size:18.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
h3
	{mso-style-link:"Heading 3 Char";
	margin-right:0in;
	margin-left:0in;
	font-size:13.5pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p
	{margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin:0in;
	margin-bottom:.0001pt;
	font-size:8.0pt;
	font-family:"Tahoma","sans-serif";}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-link:"Heading 1";
	font-family:"Times New Roman","serif";
	font-weight:bold;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	mso-style-link:"Heading 2";
	font-family:"Times New Roman","serif";
	font-weight:bold;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-link:"Heading 3";
	font-family:"Times New Roman","serif";
	font-weight:bold;}
p.ui-button, li.ui-button, div.ui-button
	{mso-style-name:ui-button;
	margin-right:1.2pt;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-spinner, li.ui-spinner, div.ui-spinner
	{mso-style-name:ui-spinner;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-spinner-input, li.ui-spinner-input, div.ui-spinner-input
	{mso-style-name:ui-spinner-input;
	margin-top:2.4pt;
	margin-right:16.5pt;
	margin-bottom:2.4pt;
	margin-left:4.8pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-helper-hidden-accessible, li.ui-helper-hidden-accessible, div.ui-helper-hidden-accessible
	{mso-style-name:ui-helper-hidden-accessible;
	margin-top:0in;
	margin-right:-.75pt;
	margin-bottom:0in;
	margin-left:-.75pt;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-buttonset, li.ui-buttonset, div.ui-buttonset
	{mso-style-name:ui-buttonset;
	margin-right:5.25pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker, li.ui-datepicker, div.ui-datepicker
	{mso-style-name:ui-datepicker;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-datepicker-row-break, li.ui-datepicker-row-break, div.ui-datepicker-row-break
	{mso-style-name:ui-datepicker-row-break;
	margin-right:0in;
	margin-left:0in;
	font-size:1.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-rtl, li.ui-datepicker-rtl, div.ui-datepicker-rtl
	{mso-style-name:ui-datepicker-rtl;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	direction:rtl;
	unicode-bidi:embed;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-menu, li.ui-menu, div.ui-menu
	{mso-style-name:ui-menu;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-progressbar, li.ui-progressbar, div.ui-progressbar
	{mso-style-name:ui-progressbar;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-handle, li.ui-resizable-handle, div.ui-resizable-handle
	{mso-style-name:ui-resizable-handle;
	margin-right:0in;
	margin-left:0in;
	font-size:1.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-n, li.ui-resizable-n, div.ui-resizable-n
	{mso-style-name:ui-resizable-n;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-s, li.ui-resizable-s, div.ui-resizable-s
	{mso-style-name:ui-resizable-s;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-e, li.ui-resizable-e, div.ui-resizable-e
	{mso-style-name:ui-resizable-e;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-w, li.ui-resizable-w, div.ui-resizable-w
	{mso-style-name:ui-resizable-w;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-se, li.ui-resizable-se, div.ui-resizable-se
	{mso-style-name:ui-resizable-se;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-sw, li.ui-resizable-sw, div.ui-resizable-sw
	{mso-style-name:ui-resizable-sw;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-nw, li.ui-resizable-nw, div.ui-resizable-nw
	{mso-style-name:ui-resizable-nw;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-ne, li.ui-resizable-ne, div.ui-resizable-ne
	{mso-style-name:ui-resizable-ne;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-selectable-helper, li.ui-selectable-helper, div.ui-selectable-helper
	{mso-style-name:ui-selectable-helper;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-selectmenu-menu, li.ui-selectmenu-menu, div.ui-selectmenu-menu
	{mso-style-name:ui-selectmenu-menu;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-selectmenu-open, li.ui-selectmenu-open, div.ui-selectmenu-open
	{mso-style-name:ui-selectmenu-open;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-selectmenu-button, li.ui-selectmenu-button, div.ui-selectmenu-button
	{mso-style-name:ui-selectmenu-button;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-slider, li.ui-slider, div.ui-slider
	{mso-style-name:ui-slider;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-slider-horizontal, li.ui-slider-horizontal, div.ui-slider-horizontal
	{mso-style-name:ui-slider-horizontal;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-slider-vertical, li.ui-slider-vertical, div.ui-slider-vertical
	{mso-style-name:ui-slider-vertical;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-spinner-button, li.ui-spinner-button, div.ui-spinner-button
	{mso-style-name:ui-spinner-button;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:6.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tooltip, li.ui-tooltip, div.ui-tooltip
	{mso-style-name:ui-tooltip;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-state-default, li.ui-state-default, div.ui-state-default
	{mso-style-name:ui-state-default;
	margin-right:0in;
	margin-left:0in;
	background:#E6E6E6;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#555555;}
p.ui-state-focus, li.ui-state-focus, div.ui-state-focus
	{mso-style-name:ui-state-focus;
	margin-right:0in;
	margin-left:0in;
	background:#DADADA;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-hover, li.ui-state-hover, div.ui-state-hover
	{mso-style-name:ui-state-hover;
	margin-right:0in;
	margin-left:0in;
	background:#DADADA;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-active, li.ui-state-active, div.ui-state-active
	{mso-style-name:ui-state-active;
	margin-right:0in;
	margin-left:0in;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-highlight, li.ui-state-highlight, div.ui-state-highlight
	{mso-style-name:ui-state-highlight;
	margin-right:0in;
	margin-left:0in;
	background:#FBF9EE;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#363636;}
p.ui-state-error, li.ui-state-error, div.ui-state-error
	{mso-style-name:ui-state-error;
	margin-right:0in;
	margin-left:0in;
	background:#FEF1EC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#CD0A0A;}
p.ui-state-error-text, li.ui-state-error-text, div.ui-state-error-text
	{mso-style-name:ui-state-error-text;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#CD0A0A;}
p.ui-priority-primary, li.ui-priority-primary, div.ui-priority-primary
	{mso-style-name:ui-priority-primary;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
p.ui-priority-secondary, li.ui-priority-secondary, div.ui-priority-secondary
	{mso-style-name:ui-priority-secondary;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-state-disabled, li.ui-state-disabled, div.ui-state-disabled
	{mso-style-name:ui-state-disabled;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-helper-hidden, li.ui-helper-hidden, div.ui-helper-hidden
	{mso-style-name:ui-helper-hidden;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-helper-reset, li.ui-helper-reset, div.ui-helper-reset
	{mso-style-name:ui-helper-reset;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-helper-zfix, li.ui-helper-zfix, div.ui-helper-zfix
	{mso-style-name:ui-helper-zfix;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-widget-overlay, li.ui-widget-overlay, div.ui-widget-overlay
	{mso-style-name:ui-widget-overlay;
	margin-right:0in;
	margin-left:0in;
	background:#AAAAAA;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-helper-clearfix, li.ui-helper-clearfix, div.ui-helper-clearfix
	{mso-style-name:ui-helper-clearfix;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon, li.ui-icon, div.ui-icon
	{mso-style-name:ui-icon;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-widget-content, li.ui-widget-content, div.ui-widget-content
	{mso-style-name:ui-widget-content;
	margin-right:0in;
	margin-left:0in;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#222222;}
p.ui-widget-header, li.ui-widget-header, div.ui-widget-header
	{mso-style-name:ui-widget-header;
	margin-right:0in;
	margin-left:0in;
	background:#CCCCCC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#222222;
	font-weight:bold;}
p.ui-widget-shadow, li.ui-widget-shadow, div.ui-widget-shadow
	{mso-style-name:ui-widget-shadow;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:-6.0pt;
	margin-bottom:.0001pt;
	background:#AAAAAA;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-widget, li.ui-widget, div.ui-widget
	{mso-style-name:ui-widget;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";}
p.ui-tabs, li.ui-tabs, div.ui-tabs
	{mso-style-name:ui-tabs;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog, li.ui-dialog, div.ui-dialog
	{mso-style-name:ui-dialog;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:10.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog-titlebar, li.ui-dialog-titlebar, div.ui-dialog-titlebar
	{mso-style-name:ui-dialog-titlebar;
	margin-right:0in;
	margin-left:0in;
	background:#3E72A6;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.ui-ncbiautocomplete-actions, li.ui-ncbiautocomplete-actions, div.ui-ncbiautocomplete-actions
	{mso-style-name:ui-ncbiautocomplete-actions;
	margin-top:.75pt;
	margin-right:-.75pt;
	margin-bottom:0in;
	margin-left:-.75pt;
	margin-bottom:.0001pt;
	background:#CECECE;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbiautocomplete-link-pref, li.ui-ncbiautocomplete-link-pref, div.ui-ncbiautocomplete-link-pref
	{mso-style-name:ui-ncbiautocomplete-link-pref;
	margin-right:0in;
	margin-left:0in;
	text-indent:-945.65pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbibutton, li.ui-ncbibutton, div.ui-ncbibutton
	{mso-style-name:ui-ncbibutton;
	margin-right:1.2pt;
	margin-left:0in;
	text-align:center;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"inherit","serif";}
p.ui-button-icon-only, li.ui-button-icon-only, div.ui-button-icon-only
	{mso-style-name:ui-button-icon-only;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-icons-only, li.ui-button-icons-only, div.ui-button-icons-only
	{mso-style-name:ui-button-icons-only;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-outer-div, li.ui-ncbigrid-outer-div, div.ui-ncbigrid-outer-div
	{mso-style-name:ui-ncbigrid-outer-div;
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:33.6pt;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-inner-div, li.ui-ncbigrid-inner-div, div.ui-ncbigrid-inner-div
	{mso-style-name:ui-ncbigrid-inner-div;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-filter-toolbar, li.ui-ncbigrid-filter-toolbar, div.ui-ncbigrid-filter-toolbar
	{mso-style-name:ui-ncbigrid-filter-toolbar;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	line-height:20.25pt;
	font-size:11.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-paged-toolbar, li.ui-ncbigrid-paged-toolbar, div.ui-ncbigrid-paged-toolbar
	{mso-style-name:ui-ncbigrid-paged-toolbar;
	margin-right:0in;
	margin-left:0in;
	line-height:19.4pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-checkbox-toolbar, li.ui-ncbigrid-checkbox-toolbar, div.ui-ncbigrid-checkbox-toolbar
	{mso-style-name:ui-ncbigrid-checkbox-toolbar;
	margin-right:0in;
	margin-left:0in;
	line-height:21.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-paged-countitems, li.ui-ncbigrid-paged-countitems, div.ui-ncbigrid-paged-countitems
	{mso-style-name:ui-ncbigrid-paged-countitems;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-paged-pagecontrol, li.ui-ncbigrid-paged-pagecontrol, div.ui-ncbigrid-paged-pagecontrol
	{mso-style-name:ui-ncbigrid-paged-pagecontrol;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	font-size:11.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-paged-toolbar-bottom, li.ui-ncbigrid-paged-toolbar-bottom, div.ui-ncbigrid-paged-toolbar-bottom
	{mso-style-name:ui-ncbigrid-paged-toolbar-bottom;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-select-question, li.ui-ncbigrid-select-question, div.ui-ncbigrid-select-question
	{mso-style-name:ui-ncbigrid-select-question;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-ncbigrid-select-question-footer, li.ui-ncbigrid-select-question-footer, div.ui-ncbigrid-select-question-footer
	{mso-style-name:ui-ncbigrid-select-question-footer;
	margin-right:0in;
	margin-left:0in;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbibasicmenu, li.ui-ncbibasicmenu, div.ui-ncbibasicmenu
	{mso-style-name:ui-ncbibasicmenu;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbibasicmenuli, li.ui-ncbibasicmenuli, div.ui-ncbibasicmenuli
	{mso-style-name:ui-ncbibasicmenu>li;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.orientationhortli, li.orientationhortli, div.orientationhortli
	{mso-style-name:orientation_hort>li;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.jig-ncbimenu, li.jig-ncbimenu, div.jig-ncbimenu
	{mso-style-name:jig-ncbimenu;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.jig-ncbimenuli, li.jig-ncbimenuli, div.jig-ncbimenuli
	{mso-style-name:jig-ncbimenu>li;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbipopper-wrapper, li.ui-ncbipopper-wrapper, div.ui-ncbipopper-wrapper
	{mso-style-name:ui-ncbipopper-wrapper;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-ncbipopper-basic, li.ui-ncbipopper-basic, div.ui-ncbipopper-basic
	{mso-style-name:ui-ncbipopper-basic;
	margin-right:0in;
	margin-left:0in;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#303030;}
p.brieflinkpopdesc, li.brieflinkpopdesc, div.brieflinkpopdesc
	{mso-style-name:brieflinkpopdesc;
	margin-top:4.8pt;
	margin-right:0in;
	margin-left:0in;
	font-size:10.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbitoggler-slave, li.ui-ncbitoggler-slave, div.ui-ncbitoggler-slave
	{mso-style-name:ui-ncbitoggler-slave;
	margin-top:2.4pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:12.0pt;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-ncbitoggler-slave-open, li.ui-ncbitoggler-slave-open, div.ui-ncbitoggler-slave-open
	{mso-style-name:ui-ncbitoggler-slave-open;
	margin-top:2.4pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:12.0pt;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbilinksmenu, li.ui-ncbilinksmenu, div.ui-ncbilinksmenu
	{mso-style-name:ui-ncbilinksmenu;
	margin-right:0in;
	margin-left:0in;
	background:#FCFCFC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#999999;
	font-weight:bold;}
p.ui-ncbilinksmenu-loadingmessage, li.ui-ncbilinksmenu-loadingmessage, div.ui-ncbilinksmenu-loadingmessage
	{mso-style-name:ui-ncbilinksmenu-loadingmessage;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbiclearbutton-wrap, li.ui-ncbiclearbutton-wrap, div.ui-ncbiclearbutton-wrap
	{mso-style-name:ui-ncbiclearbutton-wrap;
	margin-right:0in;
	margin-left:0in;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbiexpander, li.ui-ncbiexpander, div.ui-ncbiexpander
	{mso-style-name:ui-ncbiexpander;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbiexpander-simple, li.ui-ncbiexpander-simple, div.ui-ncbiexpander-simple
	{mso-style-name:ui-ncbiexpander-simple;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-expander-arrow-bar, li.ui-expander-arrow-bar, div.ui-expander-arrow-bar
	{mso-style-name:ui-expander-arrow-bar;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-expander-controllink, li.ui-expander-controllink, div.ui-expander-controllink
	{mso-style-name:ui-expander-controllink;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.jig-ncbiinpagenav-goto-container, li.jig-ncbiinpagenav-goto-container, div.jig-ncbiinpagenav-goto-container
	{mso-style-name:jig-ncbiinpagenav-goto-container;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbisetswitch, li.ui-ncbisetswitch, div.ui-ncbisetswitch
	{mso-style-name:ui-ncbisetswitch;
	margin-right:0in;
	margin-left:0in;
	background:#F6F6F6;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#444444;}
p.ui-ncbisetswitch-hasstar, li.ui-ncbisetswitch-hasstar, div.ui-ncbisetswitch-hasstar
	{mso-style-name:ui-ncbisetswitch-hasstar;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.fg-button-icon-left, li.fg-button-icon-left, div.fg-button-icon-left
	{mso-style-name:fg-button-icon-left;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.jig-ncbihistogram, li.jig-ncbihistogram, div.jig-ncbihistogram
	{mso-style-name:jig-ncbihistogram;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbihistogram, li.ui-ncbihistogram, div.ui-ncbihistogram
	{mso-style-name:ui-ncbihistogram;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbihistogram-display-area, li.ui-ncbihistogram-display-area, div.ui-ncbihistogram-display-area
	{mso-style-name:ui-ncbihistogram-display-area;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbihistogram-display-areaollih3, li.ui-ncbihistogram-display-areaollih3, div.ui-ncbihistogram-display-areaollih3
	{mso-style-name:ui-ncbihistogram-display-area>ol>li>h3;
	margin:0in;
	margin-bottom:.0001pt;
	text-indent:366.4pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbihistogram-controls, li.ui-ncbihistogram-controls, div.ui-ncbihistogram-controls
	{mso-style-name:ui-ncbihistogram-controls;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbihistogram-left, li.ui-ncbihistogram-left, div.ui-ncbihistogram-left
	{mso-style-name:ui-ncbihistogram-left;
	margin-right:0in;
	margin-left:2.25pt;
	text-align:center;
	font-size:1.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbihistogram-right, li.ui-ncbihistogram-right, div.ui-ncbihistogram-right
	{mso-style-name:ui-ncbihistogram-right;
	margin-right:2.25pt;
	margin-left:0in;
	text-align:center;
	font-size:1.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbihistogram-left-disabled, li.ui-ncbihistogram-left-disabled, div.ui-ncbihistogram-left-disabled
	{mso-style-name:ui-ncbihistogram-left-disabled;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#DDDDDD;}
p.ui-ncbihistogram-right-disabled, li.ui-ncbihistogram-right-disabled, div.ui-ncbihistogram-right-disabled
	{mso-style-name:ui-ncbihistogram-right-disabled;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#DDDDDD;}
p.ui-ncbihistogram-text, li.ui-ncbihistogram-text, div.ui-ncbihistogram-text
	{mso-style-name:ui-ncbihistogram-text;
	margin-top:0in;
	margin-right:12.75pt;
	margin-bottom:0in;
	margin-left:12.75pt;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:21.8pt;
	font-size:10.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbihistogram-tooltip, li.ui-ncbihistogram-tooltip, div.ui-ncbihistogram-tooltip
	{mso-style-name:ui-ncbihistogram-tooltip;
	margin-right:0in;
	margin-left:0in;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:black;
	display:none;}
p.ncbiactivevalidationmsg, li.ncbiactivevalidationmsg, div.ncbiactivevalidationmsg
	{mso-style-name:ncbiactivevalidation_msg;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ncbiactivevalidationmsgchecking, li.ncbiactivevalidationmsgchecking, div.ncbiactivevalidationmsgchecking
	{mso-style-name:ncbiactivevalidation_msg_checking;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#FF9900;}
p.ncbiactivevalidationmsgvalid, li.ncbiactivevalidationmsgvalid, div.ncbiactivevalidationmsgvalid
	{mso-style-name:ncbiactivevalidation_msg_valid;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:green;}
p.ncbiactivevalidationmsgerror, li.ncbiactivevalidationmsgerror, div.ncbiactivevalidationmsgerror
	{mso-style-name:ncbiactivevalidation_msg_error;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:red;}
p.ncbiactivevalidationmsginfo, li.ncbiactivevalidationmsginfo, div.ncbiactivevalidationmsginfo
	{mso-style-name:ncbiactivevalidation_msg_info;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:blue;}
p.ncbiactivevalidationelerror, li.ncbiactivevalidationelerror, div.ncbiactivevalidationelerror
	{mso-style-name:ncbiactivevalidation_el_error;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.social-buttons, li.social-buttons, div.social-buttons
	{mso-style-name:social-buttons;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.inlinelist, li.inlinelist, div.inlinelist
	{mso-style-name:inline_list;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.inline, li.inline, div.inline
	{mso-style-name:inline;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.fig, li.fig, div.fig
	{mso-style-name:fig;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.table, li.table, div.table
	{mso-style-name:table;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.pmc-wm, li.pmc-wm, div.pmc-wm
	{mso-style-name:pmc-wm;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.attic, li.attic, div.attic
	{mso-style-name:attic;
	margin-right:0in;
	margin-left:0in;
	background:#336699;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.basement, li.basement, div.basement
	{mso-style-name:basement;
	margin-right:0in;
	margin-left:0in;
	background:#336699;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.page-breadcrumbs, li.page-breadcrumbs, div.page-breadcrumbs
	{mso-style-name:page-breadcrumbs;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";}
p.first-line-outdent, li.first-line-outdent, div.first-line-outdent
	{mso-style-name:first-line-outdent;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.vatop, li.vatop, div.vatop
	{mso-style-name:va_top;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.vamiddle, li.vamiddle, div.vamiddle
	{mso-style-name:va_middle;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.qtrhythm, li.qtrhythm, div.qtrhythm
	{mso-style-name:qt_rhythm;
	margin-top:4.15pt;
	margin-right:0in;
	margin-bottom:4.15pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.notopmargin, li.notopmargin, div.notopmargin
	{mso-style-name:no_top_margin;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.nobottommargin, li.nobottommargin, div.nobottommargin
	{mso-style-name:no_bottom_margin;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.tscanvas, li.tscanvas, div.tscanvas
	{mso-style-name:ts_canvas;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.tsbar, li.tsbar, div.tsbar
	{mso-style-name:ts_bar;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#DCF0F4;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.fm-reuse, li.fm-reuse, div.fm-reuse
	{mso-style-name:fm-reuse;
	margin-right:0in;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.fm-subtitle, li.fm-subtitle, div.fm-subtitle
	{mso-style-name:fm-subtitle;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	font-size:15.0pt;
	font-family:"Times New Roman","serif";}
p.fm-copyright-license, li.fm-copyright-license, div.fm-copyright-license
	{mso-style-name:fm-copyright-license;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.fm-citation-from, li.fm-citation-from, div.fm-citation-from
	{mso-style-name:fm-citation-from;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ft-thumb-box, li.ft-thumb-box, div.ft-thumb-box
	{mso-style-name:ft-thumb-box;
	margin:8.3pt;
	text-align:center;
	background:#F8F8F8;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ft-thumb-current, li.ft-thumb-current, div.ft-thumb-current
	{mso-style-name:ft-thumb-current;
	margin-right:0in;
	margin-left:0in;
	background:#D0DCE8;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.tab, li.tab, div.tab
	{mso-style-name:tab;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#F8F8F8;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";}
p.arrowtab, li.arrowtab, div.arrowtab
	{mso-style-name:arrowtab;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#F8F8F8;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";}
p.blanktab, li.blanktab, div.blanktab
	{mso-style-name:blanktab;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#F8F8F8;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";}
p.thistab, li.thistab, div.thistab
	{mso-style-name:thistab;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";
	font-weight:bold;}
p.doi, li.doi, div.doi
	{mso-style-name:doi;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.msg-error, li.msg-error, div.msg-error
	{mso-style-name:msg-error;
	margin-right:0in;
	margin-left:0in;
	background:yellow;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:red;}
p.msg-warning, li.msg-warning, div.msg-warning
	{mso-style-name:msg-warning;
	margin-right:0in;
	margin-left:0in;
	background:yellow;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:brown;}
p.nihms-highlight, li.nihms-highlight, div.nihms-highlight
	{mso-style-name:nihms-highlight;
	margin-top:0in;
	margin-right:2.4pt;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	text-align:center;
	background:yellow;
	font-size:10.5pt;
	font-family:"Times New Roman","serif";
	color:#990000;}
p.head, li.head, div.head
	{mso-style-name:head;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.sub-head, li.sub-head, div.sub-head
	{mso-style-name:sub-head;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.headless, li.headless, div.headless
	{mso-style-name:headless;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.sub-navigation, li.sub-navigation, div.sub-navigation
	{mso-style-name:sub-navigation;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.sec, li.sec, div.sec
	{mso-style-name:sec;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.content-branding, li.content-branding, div.content-branding
	{mso-style-name:content-branding;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.banner-generic-logo-background, li.banner-generic-logo-background, div.banner-generic-logo-background
	{mso-style-name:banner-generic-logo-background;
	margin-right:0in;
	margin-left:0in;
	background:silver;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.banner-journal-name, li.banner-journal-name, div.banner-journal-name
	{mso-style-name:banner-journal-name;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:20.5pt;
	font-family:"Calibri","sans-serif";
	font-variant:small-caps;
	letter-spacing:.3pt;}
p.banner-journal-publisher-over-image, li.banner-journal-publisher-over-image, div.banner-journal-publisher-over-image
	{mso-style-name:banner-journal-publisher-over-image;
	margin-right:7.5pt;
	margin-left:63.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.banner-publisher-name, li.banner-publisher-name, div.banner-publisher-name
	{mso-style-name:banner-publisher-name;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	font-size:9.5pt;
	font-family:"Calibri","sans-serif";
	color:#AA1111;
	font-weight:bold;}
p.bl-w-jtitle-over, li.bl-w-jtitle-over, div.bl-w-jtitle-over
	{mso-style-name:bl-w-jtitle-over;
	margin-right:0in;
	margin-left:0in;
	font-size:18.0pt;
	font-family:"Times New Roman","serif";
	font-variant:small-caps;}
p.bl-w-jtitle-over-ph, li.bl-w-jtitle-over-ph, div.bl-w-jtitle-over-ph
	{mso-style-name:bl-w-jtitle-over-ph;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.bl-w-jtitle-over-ph-content, li.bl-w-jtitle-over-ph-content, div.bl-w-jtitle-over-ph-content
	{mso-style-name:bl-w-jtitle-over-ph-content;
	margin-top:3.0pt;
	margin-right:6.0pt;
	margin-bottom:3.0pt;
	margin-left:78.75pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.banner-journal-publisher-over-image-elsevierwt, li.banner-journal-publisher-over-image-elsevierwt, div.banner-journal-publisher-over-image-elsevierwt
	{mso-style-name:banner-journal-publisher-over-image-elsevierwt;
	margin-top:0in;
	margin-right:120.0pt;
	margin-bottom:0in;
	margin-left:15.0pt;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.elsevierwt-sponsored-label, li.elsevierwt-sponsored-label, div.elsevierwt-sponsored-label
	{mso-style-name:elsevierwt-sponsored-label;
	margin-right:0in;
	margin-left:-9.0pt;
	line-height:13.5pt;
	font-size:10.0pt;
	font-family:"Calibri","sans-serif";
	font-variant:small-caps;
	letter-spacing:.9pt;
	font-style:italic;}
p.bl-jtitle-sageopen, li.bl-jtitle-sageopen, div.bl-jtitle-sageopen
	{mso-style-name:bl-jtitle-sageopen;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#0055A5;}
p.bl-jtitle-iospressopenlib, li.bl-jtitle-iospressopenlib, div.bl-jtitle-iospressopenlib
	{mso-style-name:bl-jtitle-iospressopenlib;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.bl-jtitle-apasd, li.bl-jtitle-apasd, div.bl-jtitle-apasd
	{mso-style-name:bl-jtitle-apasd;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#1E73B3;}
p.bl-jtitle-springeropen, li.bl-jtitle-springeropen, div.bl-jtitle-springeropen
	{mso-style-name:bl-jtitle-springeropen;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#F0F0F0;}
p.bl-jtitle-sfesd, li.bl-jtitle-sfesd, div.bl-jtitle-sfesd
	{mso-style-name:bl-jtitle-sfesd;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.bl-jtitle-acssd, li.bl-jtitle-acssd, div.bl-jtitle-acssd
	{mso-style-name:bl-jtitle-acssd;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#1E73B3;}
p.bl-jtitle-esesd, li.bl-jtitle-esesd, div.bl-jtitle-esesd
	{mso-style-name:bl-jtitle-esesd;
	margin-right:0in;
	margin-left:0in;
	line-height:33.75pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.bl-jtitle-srfsd, li.bl-jtitle-srfsd, div.bl-jtitle-srfsd
	{mso-style-name:bl-jtitle-srfsd;
	margin-right:0in;
	margin-left:0in;
	line-height:33.75pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.bl-jtitle-tea, li.bl-jtitle-tea, div.bl-jtitle-tea
	{mso-style-name:bl-jtitle-tea;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#861316;}
p.bl-jtitle-rcpsychsd, li.bl-jtitle-rcpsychsd, div.bl-jtitle-rcpsychsd
	{mso-style-name:bl-jtitle-rcpsychsd;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#44448A;}
p.bl-jtitle-npgopen, li.bl-jtitle-npgopen, div.bl-jtitle-npgopen
	{mso-style-name:bl-jtitle-npgopen;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.bl-jtitle-maneyopen, li.bl-jtitle-maneyopen, div.bl-jtitle-maneyopen
	{mso-style-name:bl-jtitle-maneyopen;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.bl-jtitle-bmjgroup, li.bl-jtitle-bmjgroup, div.bl-jtitle-bmjgroup
	{mso-style-name:bl-jtitle-bmjgroup;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#003366;}
p.bl-jtitle-clpt, li.bl-jtitle-clpt, div.bl-jtitle-clpt
	{mso-style-name:bl-jtitle-clpt;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.bl-jtitle-nihpa-wiley, li.bl-jtitle-nihpa-wiley, div.bl-jtitle-nihpa-wiley
	{mso-style-name:bl-jtitle-nihpa-wiley;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.bl-jtitle-rsmsd, li.bl-jtitle-rsmsd, div.bl-jtitle-rsmsd
	{mso-style-name:bl-jtitle-rsmsd;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.bl-jtitle-hogrefesd, li.bl-jtitle-hogrefesd, div.bl-jtitle-hogrefesd
	{mso-style-name:bl-jtitle-hogrefesd;
	margin-right:0in;
	margin-left:0in;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#025490;}
p.mp-outer, li.mp-outer, div.mp-outer
	{mso-style-name:mp-outer;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.mp-outerdiv, li.mp-outerdiv, div.mp-outerdiv
	{mso-style-name:mp-outer>div;
	margin:1.5pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.toc-highlight1, li.toc-highlight1, div.toc-highlight1
	{mso-style-name:toc-highlight1;
	margin-right:0in;
	margin-left:0in;
	background:#FFFFD0;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.toc-highlight2, li.toc-highlight2, div.toc-highlight2
	{mso-style-name:toc-highlight2;
	margin-right:0in;
	margin-left:0in;
	background:#ACE4FF;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.toc-hl-inaugural, li.toc-hl-inaugural, div.toc-hl-inaugural
	{mso-style-name:toc-hl-inaugural;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#E64A00;}
p.courtesy-note, li.courtesy-note, div.courtesy-note
	{mso-style-name:courtesy-note;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";}
p.footer, li.footer, div.footer
	{mso-style-name:footer;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.suppmat, li.suppmat, div.suppmat
	{mso-style-name:suppmat;
	margin-top:8.3pt;
	margin-right:0in;
	margin-bottom:8.3pt;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.aligncenter, li.aligncenter, div.aligncenter
	{mso-style-name:align_center;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.mul-switcher, li.mul-switcher, div.mul-switcher
	{mso-style-name:mul-switcher;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.strong, li.strong, div.strong
	{mso-style-name:strong;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
p.red, li.red, div.red
	{mso-style-name:red;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:red;}
p.navigator, li.navigator, div.navigator
	{mso-style-name:navigator;
	margin-top:15.0pt;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#F6F6F6;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.summary, li.summary, div.summary
	{mso-style-name:summary;
	margin-top:15.0pt;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.head1a, li.head1a, div.head1a
	{mso-style-name:head1a;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.navigator-header, li.navigator-header, div.navigator-header
	{mso-style-name:navigator-header;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.navigator-footer, li.navigator-footer, div.navigator-footer
	{mso-style-name:navigator-footer;
	margin-top:7.5pt;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.navigator-bar, li.navigator-bar, div.navigator-bar
	{mso-style-name:navigator-bar;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.navigator-page, li.navigator-page, div.navigator-page
	{mso-style-name:navigator-page;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.navigator-bar-table, li.navigator-bar-table, div.navigator-bar-table
	{mso-style-name:navigator-bar-table;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.section-with-images-on-the-same-page, li.section-with-images-on-the-same-page, div.section-with-images-on-the-same-page
	{mso-style-name:section-with-images-on-the-same-page;
	margin-top:15.0pt;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.main-archive-list-of-volumes, li.main-archive-list-of-volumes, div.main-archive-list-of-volumes
	{mso-style-name:main-archive-list-of-volumes;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.archive-header, li.archive-header, div.archive-header
	{mso-style-name:archive-header;
	margin-right:0in;
	margin-bottom:7.5pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
p.journal-block-title, li.journal-block-title, div.journal-block-title
	{mso-style-name:journal-block-title;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#CCD8E4;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:black;
	font-weight:bold;}
p.vol-year-cell, li.vol-year-cell, div.vol-year-cell
	{mso-style-name:vol-year-cell;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#CCD8E4;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:black;
	font-weight:bold;}
p.issue-block, li.issue-block, div.issue-block
	{mso-style-name:issue-block;
	margin-right:0in;
	margin-left:0in;
	background:#8CACCC;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.iss-dark-row, li.iss-dark-row, div.iss-dark-row
	{mso-style-name:iss-dark-row;
	margin-right:0in;
	margin-left:0in;
	background:#EFF1F3;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.iss-light-row, li.iss-light-row, div.iss-light-row
	{mso-style-name:iss-light-row;
	margin-right:0in;
	margin-left:0in;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.iss-cell, li.iss-cell, div.iss-cell
	{mso-style-name:iss-cell;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.vol-cell, li.vol-cell, div.vol-cell
	{mso-style-name:vol-cell;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.arc-issue, li.arc-issue, div.arc-issue
	{mso-style-name:arc-issue;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#0055AA;}
p.large-thumb-canvas, li.large-thumb-canvas, div.large-thumb-canvas
	{mso-style-name:large-thumb-canvas;
	margin:8.5pt;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#444444;
	display:none;}
p.co, li.co, div.co
	{mso-style-name:co;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.co-default, li.co-default, div.co-default
	{mso-style-name:co-default;
	margin:8.5pt;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#444444;}
p.large-thumb-canvas-1, li.large-thumb-canvas-1, div.large-thumb-canvas-1
	{mso-style-name:large-thumb-canvas-1;
	margin-right:0in;
	margin-left:0in;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.co-inner, li.co-inner, div.co-inner
	{mso-style-name:co-inner;
	margin-right:0in;
	margin-left:0in;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.in-progress, li.in-progress, div.in-progress
	{mso-style-name:in-progress;
	margin:1.5pt;
	background:#444444;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.large-thumb, li.large-thumb, div.large-thumb
	{mso-style-name:large-thumb;
	margin:1.5pt;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.small-thumb-canvas, li.small-thumb-canvas, div.small-thumb-canvas
	{mso-style-name:small-thumb-canvas;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.small-thumb, li.small-thumb, div.small-thumb
	{mso-style-name:small-thumb;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.figpopup-sensitive-area, li.figpopup-sensitive-area, div.figpopup-sensitive-area
	{mso-style-name:figpopup-sensitive-area;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.print-view, li.print-view, div.print-view
	{mso-style-name:print-view;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.citationexporter-header, li.citationexporter-header, div.citationexporter-header
	{mso-style-name:citationexporter-header;
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-style:italic;}
p.citationexporter-footer, li.citationexporter-footer, div.citationexporter-footer
	{mso-style-name:citationexporter-footer;
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.mathjaxpreview, li.mathjaxpreview, div.mathjaxpreview
	{mso-style-name:mathjax_preview;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#888888;}
p.mathjaxerror, li.mathjaxerror, div.mathjaxerror
	{mso-style-name:mathjax_error;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#CC0000;
	font-style:italic;}
p.mathjaxmenu, li.mathjaxmenu, div.mathjaxmenu
	{mso-style-name:mathjax_menu;
	margin:0in;
	margin-bottom:.0001pt;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:black;}
p.mathjaxmenuitem, li.mathjaxmenuitem, div.mathjaxmenuitem
	{mso-style-name:mathjax_menuitem;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.mathjaxmenuarrow, li.mathjaxmenuarrow, div.mathjaxmenuarrow
	{mso-style-name:mathjax_menuarrow;
	margin-right:0in;
	margin-left:0in;
	font-size:9.0pt;
	font-family:"Arial Unicode MS","sans-serif";
	color:#666666;}
p.mathjaxmenucheck, li.mathjaxmenucheck, div.mathjaxmenucheck
	{mso-style-name:mathjax_menucheck;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Arial Unicode MS","sans-serif";}
p.mathjaxmenulabel, li.mathjaxmenulabel, div.mathjaxmenulabel
	{mso-style-name:mathjax_menulabel;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-style:italic;}
p.mathjaxmenurule, li.mathjaxmenurule, div.mathjaxmenurule
	{mso-style-name:mathjax_menurule;
	margin-top:3.0pt;
	margin-right:.75pt;
	margin-bottom:0in;
	margin-left:.75pt;
	margin-bottom:.0001pt;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.mathjaxmenuclose, li.mathjaxmenuclose, div.mathjaxmenuclose
	{mso-style-name:mathjax_menuclose;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:18.0pt;
	font-family:"Courier New";
	color:#F0F0F0;}
p.print-log, li.print-log, div.print-log
	{mso-style-name:print-log;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-accordion-header, li.ui-accordion-header, div.ui-accordion-header
	{mso-style-name:ui-accordion-header;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-accordion-icons, li.ui-accordion-icons, div.ui-accordion-icons
	{mso-style-name:ui-accordion-icons;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-accordion-content, li.ui-accordion-content, div.ui-accordion-content
	{mso-style-name:ui-accordion-content;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text, li.ui-button-text, div.ui-button-text
	{mso-style-name:ui-button-text;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-header, li.ui-datepicker-header, div.ui-datepicker-header
	{mso-style-name:ui-datepicker-header;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-next, li.ui-datepicker-next, div.ui-datepicker-next
	{mso-style-name:ui-datepicker-next;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-prev, li.ui-datepicker-prev, div.ui-datepicker-prev
	{mso-style-name:ui-datepicker-prev;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-title, li.ui-datepicker-title, div.ui-datepicker-title
	{mso-style-name:ui-datepicker-title;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-buttonpane, li.ui-datepicker-buttonpane, div.ui-datepicker-buttonpane
	{mso-style-name:ui-datepicker-buttonpane;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-group, li.ui-datepicker-group, div.ui-datepicker-group
	{mso-style-name:ui-datepicker-group;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog-title, li.ui-dialog-title, div.ui-dialog-title
	{mso-style-name:ui-dialog-title;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog-buttonpane, li.ui-dialog-buttonpane, div.ui-dialog-buttonpane
	{mso-style-name:ui-dialog-buttonpane;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-menu-item, li.ui-menu-item, div.ui-menu-item
	{mso-style-name:ui-menu-item;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-menu-divider, li.ui-menu-divider, div.ui-menu-divider
	{mso-style-name:ui-menu-divider;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-progressbar-value, li.ui-progressbar-value, div.ui-progressbar-value
	{mso-style-name:ui-progressbar-value;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-progressbar-overlay, li.ui-progressbar-overlay, div.ui-progressbar-overlay
	{mso-style-name:ui-progressbar-overlay;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-slider-handle, li.ui-slider-handle, div.ui-slider-handle
	{mso-style-name:ui-slider-handle;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-slider-range, li.ui-slider-range, div.ui-slider-range
	{mso-style-name:ui-slider-range;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tabs-nav, li.ui-tabs-nav, div.ui-tabs-nav
	{mso-style-name:ui-tabs-nav;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tabs-panel, li.ui-tabs-panel, div.ui-tabs-panel
	{mso-style-name:ui-tabs-panel;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tabs-hide, li.ui-tabs-hide, div.ui-tabs-hide
	{mso-style-name:ui-tabs-hide;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog-titlebar-close, li.ui-dialog-titlebar-close, div.ui-dialog-titlebar-close
	{mso-style-name:ui-dialog-titlebar-close;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog-content, li.ui-dialog-content, div.ui-dialog-content
	{mso-style-name:ui-dialog-content;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbiautocomplete-link-pref-right, li.ui-ncbiautocomplete-link-pref-right, div.ui-ncbiautocomplete-link-pref-right
	{mso-style-name:ui-ncbiautocomplete-link-pref-right;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-icon-primary, li.ui-button-icon-primary, div.ui-button-icon-primary
	{mso-style-name:ui-button-icon-primary;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-icon-secondary, li.ui-button-icon-secondary, div.ui-button-icon-secondary
	{mso-style-name:ui-button-icon-secondary;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.prev, li.prev, div.prev
	{mso-style-name:prev;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.next, li.next, div.next
	{mso-style-name:next;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-select-row-count, li.ui-ncbigrid-select-row-count, div.ui-ncbigrid-select-row-count
	{mso-style-name:ui-ncbigrid-select-row-count;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbibasicmenulia, li.ui-ncbibasicmenulia, div.ui-ncbibasicmenulia
	{mso-style-name:ui-ncbibasicmenu>li>a;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbimenu-item-leaf, li.ui-ncbimenu-item-leaf, div.ui-ncbimenu-item-leaf
	{mso-style-name:ui-ncbimenu-item-leaf;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.brieflinkpop, li.brieflinkpop, div.brieflinkpop
	{mso-style-name:brieflinkpop;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.star, li.star, div.star
	{mso-style-name:star;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.jig-ncbisetswitch, li.jig-ncbisetswitch, div.jig-ncbisetswitch
	{mso-style-name:jig-ncbisetswitch;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbisetswitch-button, li.ui-ncbisetswitch-button, div.ui-ncbisetswitch-button
	{mso-style-name:ui-ncbisetswitch-button;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbisetswitch-options, li.ui-ncbisetswitch-options, div.ui-ncbisetswitch-options
	{mso-style-name:ui-ncbisetswitch-options;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.boxed-text-box, li.boxed-text-box, div.boxed-text-box
	{mso-style-name:boxed-text-box;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.cell-from, li.cell-from, div.cell-from
	{mso-style-name:cell-from;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.cell-citation, li.cell-citation, div.cell-citation
	{mso-style-name:cell-citation;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.figpopup, li.figpopup, div.figpopup
	{mso-style-name:figpopup;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.button, li.button, div.button
	{mso-style-name:button;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.retraction, li.retraction, div.retraction
	{mso-style-name:retraction;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.mathjaxhoverarrow, li.mathjaxhoverarrow, div.mathjaxhoverarrow
	{mso-style-name:mathjax_hover_arrow;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.pbody, li.pbody, div.pbody
	{mso-style-name:pbody;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.page-box, li.page-box, div.page-box
	{mso-style-name:page-box;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.page-box-wide, li.page-box-wide, div.page-box-wide
	{mso-style-name:page-box-wide;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.nomaxwidth, li.nomaxwidth, div.nomaxwidth
	{mso-style-name:no_max_width;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.f, li.f, div.f
	{mso-style-name:f;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.l, li.l, div.l
	{mso-style-name:l;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-accordion-header-icon, li.ui-accordion-header-icon, div.ui-accordion-header-icon
	{mso-style-name:ui-accordion-header-icon;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-selectmenu-optgroup, li.ui-selectmenu-optgroup, div.ui-selectmenu-optgroup
	{mso-style-name:ui-selectmenu-optgroup;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tabs-anchor, li.ui-tabs-anchor, div.ui-tabs-anchor
	{mso-style-name:ui-tabs-anchor;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbibutton-submit, li.ui-ncbibutton-submit, div.ui-ncbibutton-submit
	{mso-style-name:ui-ncbibutton-submit;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbibutton-cancel, li.ui-ncbibutton-cancel, div.ui-ncbibutton-cancel
	{mso-style-name:ui-ncbibutton-cancel;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ltd-hover, li.ltd-hover, div.ltd-hover
	{mso-style-name:ltd-hover;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.warn, li.warn, div.warn
	{mso-style-name:warn;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.notice, li.notice, div.notice
	{mso-style-name:notice;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.content, li.content, div.content
	{mso-style-name:content;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.onelinesource, li.onelinesource, div.onelinesource
	{mso-style-name:one_line_source;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.tertiary, li.tertiary, div.tertiary
	{mso-style-name:tertiary;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.mathjaxhoverframe, li.mathjaxhoverframe, div.mathjaxhoverframe
	{mso-style-name:mathjax_hover_frame;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
span.other-issues
	{mso-style-name:other-issues;}
span.underline
	{mso-style-name:underline;}
span.double-underline
	{mso-style-name:double-underline;}
span.bold-double-underline
	{mso-style-name:bold-double-underline;}
span.ui-icon1
	{mso-style-name:ui-icon1;}
span.ui-selectmenu-text
	{mso-style-name:ui-selectmenu-text;}
span.pagelink
	{mso-style-name:page_link;}
span.ui-icon-plus-minus-big
	{mso-style-name:ui-icon-plus-minus-big;}
span.ui-icon-plus-minus-big-open
	{mso-style-name:ui-icon-plus-minus-big-open;}
span.collapsabletbodyicon
	{mso-style-name:collapsabletbodyicon;}
p.ui-accordion-header1, li.ui-accordion-header1, div.ui-accordion-header1
	{mso-style-name:ui-accordion-header1;
	margin-top:1.5pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-accordion-icons1, li.ui-accordion-icons1, div.ui-accordion-icons1
	{mso-style-name:ui-accordion-icons1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-accordion-icons2, li.ui-accordion-icons2, div.ui-accordion-icons2
	{mso-style-name:ui-accordion-icons2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-accordion-header-icon1, li.ui-accordion-header-icon1, div.ui-accordion-header-icon1
	{mso-style-name:ui-accordion-header-icon1;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-accordion-content1, li.ui-accordion-content1, div.ui-accordion-content1
	{mso-style-name:ui-accordion-content1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text1, li.ui-button-text1, div.ui-button-text1
	{mso-style-name:ui-button-text1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text2, li.ui-button-text2, div.ui-button-text2
	{mso-style-name:ui-button-text2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text3, li.ui-button-text3, div.ui-button-text3
	{mso-style-name:ui-button-text3;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon2, li.ui-icon2, div.ui-icon2
	{mso-style-name:ui-icon2;
	margin-top:0in;
	margin-right:0in;
	margin-left:-6.0pt;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button1, li.ui-button1, div.ui-button1
	{mso-style-name:ui-button1;
	margin-right:-.05in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-header1, li.ui-datepicker-header1, div.ui-datepicker-header1
	{mso-style-name:ui-datepicker-header1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-next1, li.ui-datepicker-next1, div.ui-datepicker-next1
	{mso-style-name:ui-datepicker-next1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-prev1, li.ui-datepicker-prev1, div.ui-datepicker-prev1
	{mso-style-name:ui-datepicker-prev1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-title1, li.ui-datepicker-title1, div.ui-datepicker-title1
	{mso-style-name:ui-datepicker-title1;
	margin-top:0in;
	margin-right:27.6pt;
	margin-bottom:0in;
	margin-left:27.6pt;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:21.6pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-buttonpane1, li.ui-datepicker-buttonpane1, div.ui-datepicker-buttonpane1
	{mso-style-name:ui-datepicker-buttonpane1;
	margin-top:8.4pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-group1, li.ui-datepicker-group1, div.ui-datepicker-group1
	{mso-style-name:ui-datepicker-group1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-group2, li.ui-datepicker-group2, div.ui-datepicker-group2
	{mso-style-name:ui-datepicker-group2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-group3, li.ui-datepicker-group3, div.ui-datepicker-group3
	{mso-style-name:ui-datepicker-group3;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-header2, li.ui-datepicker-header2, div.ui-datepicker-header2
	{mso-style-name:ui-datepicker-header2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-header3, li.ui-datepicker-header3, div.ui-datepicker-header3
	{mso-style-name:ui-datepicker-header3;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-buttonpane2, li.ui-datepicker-buttonpane2, div.ui-datepicker-buttonpane2
	{mso-style-name:ui-datepicker-buttonpane2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-buttonpane3, li.ui-datepicker-buttonpane3, div.ui-datepicker-buttonpane3
	{mso-style-name:ui-datepicker-buttonpane3;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-header4, li.ui-datepicker-header4, div.ui-datepicker-header4
	{mso-style-name:ui-datepicker-header4;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-header5, li.ui-datepicker-header5, div.ui-datepicker-header5
	{mso-style-name:ui-datepicker-header5;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog-title1, li.ui-dialog-title1, div.ui-dialog-title1
	{mso-style-name:ui-dialog-title1;
	margin-top:1.2pt;
	margin-right:12.0pt;
	margin-bottom:2.4pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog-buttonpane1, li.ui-dialog-buttonpane1, div.ui-dialog-buttonpane1
	{mso-style-name:ui-dialog-buttonpane1;
	margin-top:6.0pt;
	margin-right:0in;
	margin-left:0in;
	background:whitesmoke;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-menu-item1, li.ui-menu-item1, div.ui-menu-item1
	{mso-style-name:ui-menu-item1;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-menu-divider1, li.ui-menu-divider1, div.ui-menu-divider1
	{mso-style-name:ui-menu-divider1;
	margin-top:3.75pt;
	margin-right:0in;
	margin-bottom:3.75pt;
	margin-left:0in;
	line-height:0%;
	font-size:1.0pt;
	font-family:"Times New Roman","serif";}
p.ui-state-active1, li.ui-state-active1, div.ui-state-active1
	{mso-style-name:ui-state-active1;
	margin-top:0in;
	margin-right:-.75pt;
	margin-bottom:0in;
	margin-left:-.75pt;
	margin-bottom:.0001pt;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-focus1, li.ui-state-focus1, div.ui-state-focus1
	{mso-style-name:ui-state-focus1;
	margin-top:0in;
	margin-right:-.75pt;
	margin-bottom:0in;
	margin-left:-.75pt;
	margin-bottom:.0001pt;
	background:#DADADA;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-menu-item2, li.ui-menu-item2, div.ui-menu-item2
	{mso-style-name:ui-menu-item2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon3, li.ui-icon3, div.ui-icon3
	{mso-style-name:ui-icon3;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-progressbar-value1, li.ui-progressbar-value1, div.ui-progressbar-value1
	{mso-style-name:ui-progressbar-value1;
	margin-top:0in;
	margin-right:-.75pt;
	margin-bottom:0in;
	margin-left:-.75pt;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-progressbar-overlay1, li.ui-progressbar-overlay1, div.ui-progressbar-overlay1
	{mso-style-name:ui-progressbar-overlay1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-progressbar-value2, li.ui-progressbar-value2, div.ui-progressbar-value2
	{mso-style-name:ui-progressbar-value2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-handle1, li.ui-resizable-handle1, div.ui-resizable-handle1
	{mso-style-name:ui-resizable-handle1;
	margin-right:0in;
	margin-left:0in;
	font-size:1.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-resizable-handle2, li.ui-resizable-handle2, div.ui-resizable-handle2
	{mso-style-name:ui-resizable-handle2;
	margin-right:0in;
	margin-left:0in;
	font-size:1.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-menu1, li.ui-menu1, div.ui-menu1
	{mso-style-name:ui-menu1;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-selectmenu-optgroup1, li.ui-selectmenu-optgroup1, div.ui-selectmenu-optgroup1
	{mso-style-name:ui-selectmenu-optgroup1;
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
span.ui-icon4
	{mso-style-name:ui-icon4;}
span.ui-selectmenu-text1
	{mso-style-name:ui-selectmenu-text1;}
p.ui-slider-handle1, li.ui-slider-handle1, div.ui-slider-handle1
	{mso-style-name:ui-slider-handle1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-slider-range1, li.ui-slider-range1, div.ui-slider-range1
	{mso-style-name:ui-slider-range1;
	margin-right:0in;
	margin-left:0in;
	font-size:8.5pt;
	font-family:"Times New Roman","serif";}
p.ui-slider-handle2, li.ui-slider-handle2, div.ui-slider-handle2
	{mso-style-name:ui-slider-handle2;
	margin-right:0in;
	margin-left:-.1in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-slider-handle3, li.ui-slider-handle3, div.ui-slider-handle3
	{mso-style-name:ui-slider-handle3;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-slider-range2, li.ui-slider-range2, div.ui-slider-range2
	{mso-style-name:ui-slider-range2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon5, li.ui-icon5, div.ui-icon5
	{mso-style-name:ui-icon5;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tabs-anchor1, li.ui-tabs-anchor1, div.ui-tabs-anchor1
	{mso-style-name:ui-tabs-anchor1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tooltip1, li.ui-tooltip1, div.ui-tooltip1
	{mso-style-name:ui-tooltip1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-widget1, li.ui-widget1, div.ui-widget1
	{mso-style-name:ui-widget1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";}
p.ui-state-default1, li.ui-state-default1, div.ui-state-default1
	{mso-style-name:ui-state-default1;
	margin-right:0in;
	margin-left:0in;
	background:#E6E6E6;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#555555;}
p.ui-state-default2, li.ui-state-default2, div.ui-state-default2
	{mso-style-name:ui-state-default2;
	margin-right:0in;
	margin-left:0in;
	background:#E6E6E6;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#555555;}
p.ui-state-focus2, li.ui-state-focus2, div.ui-state-focus2
	{mso-style-name:ui-state-focus2;
	margin-right:0in;
	margin-left:0in;
	background:#DADADA;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-hover1, li.ui-state-hover1, div.ui-state-hover1
	{mso-style-name:ui-state-hover1;
	margin-right:0in;
	margin-left:0in;
	background:#DADADA;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-focus3, li.ui-state-focus3, div.ui-state-focus3
	{mso-style-name:ui-state-focus3;
	margin-right:0in;
	margin-left:0in;
	background:#DADADA;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-hover2, li.ui-state-hover2, div.ui-state-hover2
	{mso-style-name:ui-state-hover2;
	margin-right:0in;
	margin-left:0in;
	background:#DADADA;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-active2, li.ui-state-active2, div.ui-state-active2
	{mso-style-name:ui-state-active2;
	margin-right:0in;
	margin-left:0in;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-active3, li.ui-state-active3, div.ui-state-active3
	{mso-style-name:ui-state-active3;
	margin-right:0in;
	margin-left:0in;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-highlight1, li.ui-state-highlight1, div.ui-state-highlight1
	{mso-style-name:ui-state-highlight1;
	margin-right:0in;
	margin-left:0in;
	background:#FBF9EE;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#363636;}
p.ui-state-highlight2, li.ui-state-highlight2, div.ui-state-highlight2
	{mso-style-name:ui-state-highlight2;
	margin-right:0in;
	margin-left:0in;
	background:#FBF9EE;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#363636;}
p.ui-state-error1, li.ui-state-error1, div.ui-state-error1
	{mso-style-name:ui-state-error1;
	margin-right:0in;
	margin-left:0in;
	background:#FEF1EC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#CD0A0A;}
p.ui-state-error2, li.ui-state-error2, div.ui-state-error2
	{mso-style-name:ui-state-error2;
	margin-right:0in;
	margin-left:0in;
	background:#FEF1EC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#CD0A0A;}
p.ui-state-error-text1, li.ui-state-error-text1, div.ui-state-error-text1
	{mso-style-name:ui-state-error-text1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#CD0A0A;}
p.ui-state-error-text2, li.ui-state-error-text2, div.ui-state-error-text2
	{mso-style-name:ui-state-error-text2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#CD0A0A;}
p.ui-priority-primary1, li.ui-priority-primary1, div.ui-priority-primary1
	{mso-style-name:ui-priority-primary1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
p.ui-priority-primary2, li.ui-priority-primary2, div.ui-priority-primary2
	{mso-style-name:ui-priority-primary2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
p.ui-priority-secondary1, li.ui-priority-secondary1, div.ui-priority-secondary1
	{mso-style-name:ui-priority-secondary1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-priority-secondary2, li.ui-priority-secondary2, div.ui-priority-secondary2
	{mso-style-name:ui-priority-secondary2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-state-disabled1, li.ui-state-disabled1, div.ui-state-disabled1
	{mso-style-name:ui-state-disabled1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-state-disabled2, li.ui-state-disabled2, div.ui-state-disabled2
	{mso-style-name:ui-state-disabled2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon6, li.ui-icon6, div.ui-icon6
	{mso-style-name:ui-icon6;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon7, li.ui-icon7, div.ui-icon7
	{mso-style-name:ui-icon7;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon8, li.ui-icon8, div.ui-icon8
	{mso-style-name:ui-icon8;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon9, li.ui-icon9, div.ui-icon9
	{mso-style-name:ui-icon9;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon10, li.ui-icon10, div.ui-icon10
	{mso-style-name:ui-icon10;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon11, li.ui-icon11, div.ui-icon11
	{mso-style-name:ui-icon11;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon12, li.ui-icon12, div.ui-icon12
	{mso-style-name:ui-icon12;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon13, li.ui-icon13, div.ui-icon13
	{mso-style-name:ui-icon13;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon14, li.ui-icon14, div.ui-icon14
	{mso-style-name:ui-icon14;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tabs-nav1, li.ui-tabs-nav1, div.ui-tabs-nav1
	{mso-style-name:ui-tabs-nav1;
	margin:0in;
	margin-bottom:.0001pt;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.tertiary1, li.tertiary1, div.tertiary1
	{mso-style-name:tertiary1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#666666;}
p.tertiary2, li.tertiary2, div.tertiary2
	{mso-style-name:tertiary2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#985735;}
p.ui-tabs-panel1, li.ui-tabs-panel1, div.ui-tabs-panel1
	{mso-style-name:ui-tabs-panel1;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tabs-hide1, li.ui-tabs-hide1, div.ui-tabs-hide1
	{mso-style-name:ui-tabs-hide1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-dialog-titlebar1, li.ui-dialog-titlebar1, div.ui-dialog-titlebar1
	{mso-style-name:ui-dialog-titlebar1;
	margin-right:0in;
	margin-left:0in;
	background:#3E72A6;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.ui-dialog-titlebar-close1, li.ui-dialog-titlebar-close1, div.ui-dialog-titlebar-close1
	{mso-style-name:ui-dialog-titlebar-close1;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog-content1, li.ui-dialog-content1, div.ui-dialog-content1
	{mso-style-name:ui-dialog-content1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-se1, li.ui-resizable-se1, div.ui-resizable-se1
	{mso-style-name:ui-resizable-se1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon15, li.ui-icon15, div.ui-icon15
	{mso-style-name:ui-icon15;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-state-hover3, li.ui-state-hover3, div.ui-state-hover3
	{mso-style-name:ui-state-hover3;
	margin-right:0in;
	margin-left:0in;
	background:#DADADA;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-ncbibutton-submit1, li.ui-ncbibutton-submit1, div.ui-ncbibutton-submit1
	{mso-style-name:ui-ncbibutton-submit1;
	margin-right:6.55pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbibutton-cancel1, li.ui-ncbibutton-cancel1, div.ui-ncbibutton-cancel1
	{mso-style-name:ui-ncbibutton-cancel1;
	margin-right:0in;
	margin-left:0in;
	line-height:22.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#2F4A8B;}
p.ui-button-text4, li.ui-button-text4, div.ui-button-text4
	{mso-style-name:ui-button-text4;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbiautocomplete-link-pref-right1, li.ui-ncbiautocomplete-link-pref-right1, div.ui-ncbiautocomplete-link-pref-right1
	{mso-style-name:ui-ncbiautocomplete-link-pref-right1;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text5, li.ui-button-text5, div.ui-button-text5
	{mso-style-name:ui-button-text5;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text6, li.ui-button-text6, div.ui-button-text6
	{mso-style-name:ui-button-text6;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text7, li.ui-button-text7, div.ui-button-text7
	{mso-style-name:ui-button-text7;
	margin-right:0in;
	margin-left:0in;
	text-indent:595.95pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text8, li.ui-button-text8, div.ui-button-text8
	{mso-style-name:ui-button-text8;
	margin-right:0in;
	margin-left:0in;
	text-indent:595.95pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text9, li.ui-button-text9, div.ui-button-text9
	{mso-style-name:ui-button-text9;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text10, li.ui-button-text10, div.ui-button-text10
	{mso-style-name:ui-button-text10;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon16, li.ui-icon16, div.ui-icon16
	{mso-style-name:ui-icon16;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon17, li.ui-icon17, div.ui-icon17
	{mso-style-name:ui-icon17;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon18, li.ui-icon18, div.ui-icon18
	{mso-style-name:ui-icon18;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon19, li.ui-icon19, div.ui-icon19
	{mso-style-name:ui-icon19;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon20, li.ui-icon20, div.ui-icon20
	{mso-style-name:ui-icon20;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon21, li.ui-icon21, div.ui-icon21
	{mso-style-name:ui-icon21;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-icon-primary1, li.ui-button-icon-primary1, div.ui-button-icon-primary1
	{mso-style-name:ui-button-icon-primary1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-icon-primary2, li.ui-button-icon-primary2, div.ui-button-icon-primary2
	{mso-style-name:ui-button-icon-primary2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-icon-primary3, li.ui-button-icon-primary3, div.ui-button-icon-primary3
	{mso-style-name:ui-button-icon-primary3;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-icon-secondary1, li.ui-button-icon-secondary1, div.ui-button-icon-secondary1
	{mso-style-name:ui-button-icon-secondary1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-icon-secondary2, li.ui-button-icon-secondary2, div.ui-button-icon-secondary2
	{mso-style-name:ui-button-icon-secondary2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-paged-pagecontrol1, li.ui-ncbigrid-paged-pagecontrol1, div.ui-ncbigrid-paged-pagecontrol1
	{mso-style-name:ui-ncbigrid-paged-pagecontrol1;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	font-size:11.0pt;
	font-family:"Times New Roman","serif";}
p.prev1, li.prev1, div.prev1
	{mso-style-name:prev1;
	margin-right:.1in;
	margin-left:2.4pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.next1, li.next1, div.next1
	{mso-style-name:next1;
	margin-right:2.4pt;
	margin-left:.1in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-select-row-count1, li.ui-ncbigrid-select-row-count1, div.ui-ncbigrid-select-row-count1
	{mso-style-name:ui-ncbigrid-select-row-count1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
span.pagelink1
	{mso-style-name:page_link1;
	color:#CCCCCC;}
span.collapsabletbodyicon1
	{mso-style-name:collapsabletbodyicon1;}
span.ui-icon-plus-minus-big1
	{mso-style-name:ui-icon-plus-minus-big1;}
span.ui-icon-plus-minus-big-open1
	{mso-style-name:ui-icon-plus-minus-big-open1;}
p.ui-ncbigrid-outer-div1, li.ui-ncbigrid-outer-div1, div.ui-ncbigrid-outer-div1
	{mso-style-name:ui-ncbigrid-outer-div1;
	margin:0in;
	margin-bottom:.0001pt;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbimenu-item-leaf1, li.ui-ncbimenu-item-leaf1, div.ui-ncbimenu-item-leaf1
	{mso-style-name:ui-ncbimenu-item-leaf1;
	margin-top:0in;
	margin-right:9.0pt;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.brieflinkpop1, li.brieflinkpop1, div.brieflinkpop1
	{mso-style-name:brieflinkpop1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
span.ui-icon-plus-minus-big2
	{mso-style-name:ui-icon-plus-minus-big2;}
span.ui-icon-plus-minus-big-open2
	{mso-style-name:ui-icon-plus-minus-big-open2;}
span.ui-icon22
	{mso-style-name:ui-icon22;}
span.ui-icon23
	{mso-style-name:ui-icon23;}
p.star1, li.star1, div.star1
	{mso-style-name:star1;
	margin-right:7.4pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.jig-ncbisetswitch1, li.jig-ncbisetswitch1, div.jig-ncbisetswitch1
	{mso-style-name:jig-ncbisetswitch1;
	margin-right:0in;
	margin-left:0in;
	line-height:14.75pt;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#333333;}
p.ui-ncbisetswitch-button1, li.ui-ncbisetswitch-button1, div.ui-ncbisetswitch-button1
	{mso-style-name:ui-ncbisetswitch-button1;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon24, li.ui-icon24, div.ui-icon24
	{mso-style-name:ui-icon24;
	margin:5.55pt;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ltd-hover1, li.ltd-hover1, div.ltd-hover1
	{mso-style-name:ltd-hover1;
	margin-right:0in;
	margin-left:0in;
	background:#E8E8E8;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon25, li.ui-icon25, div.ui-icon25
	{mso-style-name:ui-icon25;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbisetswitch-options1, li.ui-ncbisetswitch-options1, div.ui-ncbisetswitch-options1
	{mso-style-name:ui-ncbisetswitch-options1;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.pbody1, li.pbody1, div.pbody1
	{mso-style-name:pbody1;
	margin-top:0in;
	margin-right:16.6pt;
	margin-bottom:0in;
	margin-left:16.6pt;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.page-box1, li.page-box1, div.page-box1
	{mso-style-name:page-box1;
	margin-top:16.6pt;
	margin-right:0in;
	margin-bottom:16.6pt;
	margin-left:0in;
	background:#F8F8F8;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.page-box-wide1, li.page-box-wide1, div.page-box-wide1
	{mso-style-name:page-box-wide1;
	margin-top:16.6pt;
	margin-right:0in;
	margin-bottom:16.6pt;
	margin-left:0in;
	background:#F8F8F8;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.nomaxwidth1, li.nomaxwidth1, div.nomaxwidth1
	{mso-style-name:no_max_width1;
	margin-right:0in;
	margin-left:0in;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.content1, li.content1, div.content1
	{mso-style-name:content1;
	margin:16.6pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.boxed-text-box1, li.boxed-text-box1, div.boxed-text-box1
	{mso-style-name:boxed-text-box1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.f1, li.f1, div.f1
	{mso-style-name:f1;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.l1, li.l1, div.l1
	{mso-style-name:l1;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.cell-from1, li.cell-from1, div.cell-from1
	{mso-style-name:cell-from1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
p.cell-citation1, li.cell-citation1, div.cell-citation1
	{mso-style-name:cell-citation1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.figpopup1, li.figpopup1, div.figpopup1
	{mso-style-name:figpopup1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.button1, li.button1, div.button1
	{mso-style-name:button1;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#336699;}
p.retraction1, li.retraction1, div.retraction1
	{mso-style-name:retraction1;
	margin-right:0in;
	margin-left:0in;
	background:red;
	font-size:12.0pt;
	font-family:"Helvetica","sans-serif";
	color:#F0F0F0;}
p.warn1, li.warn1, div.warn1
	{mso-style-name:warn1;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.notice1, li.notice1, div.notice1
	{mso-style-name:notice1;
	margin-right:0in;
	margin-left:0in;
	font-size:16.5pt;
	font-family:"Times New Roman","serif";}
p.arrowtab1, li.arrowtab1, div.arrowtab1
	{mso-style-name:arrowtab1;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#F8F8F8;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";}
p.thistab1, li.thistab1, div.thistab1
	{mso-style-name:thistab1;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#F6F6F6;
	border:none;
	padding:0in;
	font-size:9.5pt;
	font-family:"Arial","sans-serif";
	font-weight:bold;}
p.onelinesource1, li.onelinesource1, div.onelinesource1
	{mso-style-name:one_line_source1;
	margin-right:0in;
	margin-left:0in;
	background:#E0E0E0;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.mathjaxhoverarrow1, li.mathjaxhoverarrow1, div.mathjaxhoverarrow1
	{mso-style-name:mathjax_hover_arrow1;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:7.0pt;
	font-family:"Courier New";
	color:#F0F0F0;}
p.mathjaxmenuarrow1, li.mathjaxmenuarrow1, div.mathjaxmenuarrow1
	{mso-style-name:mathjax_menuarrow1;
	margin-right:0in;
	margin-left:0in;
	font-size:9.0pt;
	font-family:"Arial Unicode MS","sans-serif";
	color:white;}
span.cit
	{mso-style-name:cit;}
span.fm-vol-iss-date
	{mso-style-name:fm-vol-iss-date;}
span.doi1
	{mso-style-name:doi1;}
span.fm-citation-ids-label
	{mso-style-name:fm-citation-ids-label;}
span.before-email-separator
	{mso-style-name:before-email-separator;}
span.email-label
	{mso-style-name:email-label;}
p.p, li.p, div.p
	{mso-style-name:p;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
span.kwd-text
	{mso-style-name:kwd-text;}
span.small-caps
	{mso-style-name:small-caps;}
span.citation
	{mso-style-name:citation;}
span.ref-journal
	{mso-style-name:ref-journal;}
span.ref-vol
	{mso-style-name:ref-vol;}
span.nowrap
	{mso-style-name:nowrap;}
span.ref-title
	{mso-style-name:ref-title;}
span.acknowledgment-journal-title
	{mso-style-name:acknowledgment-journal-title;}
span.star2
	{mso-style-name:star2;}
span.z-TopofFormChar
	{mso-style-name:"z-Top of Form Char";
	mso-style-link:"z-Top of Form";
	font-family:"Arial","sans-serif";
	display:none;}
span.z-BottomofFormChar
	{mso-style-name:"z-Bottom of Form Char";
	mso-style-link:"z-Bottom of Form";
	font-family:"Arial","sans-serif";
	display:none;}
span.source
	{mso-style-name:source;}
p.hton, li.hton, div.hton
	{mso-style-name:hton;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.htoff, li.htoff, div.htoff
	{mso-style-name:htoff;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";
	font-family:"Tahoma","sans-serif";}
.MsoChpDefault
	{font-family:"Calibri","sans-serif";}
.MsoPapDefault
	{margin-bottom:10.0pt;
	line-height:115%;}
@page WordSection1
	{size:8.5in 11.0in;
	margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink=purple>

<div class=WordSection1>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span style='position:absolute;z-index:251658240;margin-left:185px;
margin-top:2px;width:313px;height:71px'><img width=313 height=71
src="PMC2676548%20table%201_files/image001.png"></span><span style='font-size:
12.0pt;font-family:"Times New Roman","serif"'><img width=500 height=75
id="Picture 14" src="PMC2676548%20table%201_files/image002.gif"
alt="Logo of brjcancer"></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Br
J Cancer. 2009 Apr 21; 100(8): 12671276. </span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Published
online 2009 Mar 24. doi:&nbsp; <a
href="http://dx.doi.org/10.1038%2Fsj.bjc.6604995" target="pmc_ext">10.1038/sj.bjc.6604995</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PMCID:
PMC2676548</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:24.0pt;font-family:"Times New Roman","serif"'>Activity of a
novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human
pancreatic cancers grown as orthotopic xenografts</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Cao%20P%5Bauth%5D">P Cao</a>,<sup>1</sup>
<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Maira%20SM%5Bauth%5D">S-M
Maira</a>,<sup>2</sup> <a
href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Garc%26%23x000ed%3Ba-Echeverr%26%23x000ed%3Ba%20C%5Bauth%5D">C
Garca-Echeverra</a>,<sup>2</sup> and <a
href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Hedley%20DW%5Bauth%5D">D W
Hedley</a><sup>1,*</sup></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><sup><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>1</span></sup><span lang=EN style='font-size:12.0pt;font-family:
"Times New Roman","serif";display:none'>Division of Applied Molecular Oncology,
Department of Medical Oncology and Hematology, Ontario Cancer
Institute/Princess Margaret Hospital, University of Toronto, Ontario, Canada</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><sup><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>2</span></sup><span lang=EN style='font-size:12.0pt;font-family:
"Times New Roman","serif";display:none'>Novartis Institutes for Biomedical
Research, Oncology Disease Area, Basel CH4002, Switzerland</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><sup><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>*</span></sup><span lang=EN style='font-size:12.0pt;font-family:
"Times New Roman","serif";display:none'>Author for correspondence: Email: <a
href="mailto:dev@null">ac.no.nhu@yeldeh.divad</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/">Author information
&#9658;</a> <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/">Article
notes &#9658;</a> <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/">Copyright
and License information &#9658;</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>Revised 2009 Feb 3; Accepted 2009 Feb 26.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'><a href="http://www.ncbi.nlm.nih.gov/pmc/about/copyright.html">Copyright</a>
2009, Cancer Research UK</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>This
article has been <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/citedby/">cited by</a>
other articles in PMC.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/"
title="Go to other sections in this page">Go to:</a></span></p>

<div style='border:none;border-bottom:solid #97B0C8 1.0pt;padding:0in 0in 0in 0in'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN style='font-size:18.0pt;font-family:"Times New Roman","serif";
text-transform:uppercase'>Abstract</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>The phosphatidylinositol-3-kinase
(PI3K)/Akt signalling pathway is frequently deregulated in pancreatic cancers,
and is believed to be an important determinant of their biological aggression
and drug resistance. NVP-BEZ235 is a novel, dual class I PI3K/mammalian target
of rapamycin (mTor) inhibitor undergoing phase I human clinical trials. To
simulate clinical testing, the effects of NVP-BEZ235 were studied in five early
passage primary pancreatic cancer xenografts, grown orthotopically. These
tumours showed activated PKB/Akt, and increased levels of at least one of the
receptor tyrosine kinases that are commonly activated in pancreatic cancers.
Pharmacodynamic effects were measured following acute single doses, and
anticancer effects were determined in separate groups following chronic drug
exposure. Acute oral dosing with NVP-BEZ235 strongly suppressed the
phosphorylation of PKB/Akt, followed by recovery over 24&#8201;h. There was
also inhibition of Ser235/236 S6 ribosomal protein and Thr37/46 4E-BP1,
consistent with the effects of NVP-BEZ235 as a dual PI3K/mTor inhibitor.
Chronic dosing with 45&#8201;mg&#8201;kg<sup>&#8722;1</sup> of NVP-BEZ235 was
well tolerated, and produced significant tumour growth inhibition in three
models. These results predict that agents targeting the PI3K/Akt/mTor pathway
might have anticancer activity in pancreatic cancer patients, and support the
testing of combination studies involving chemotherapy or other molecular
targeted agents.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><b><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Keywords:
</span></b><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>pancreatic
cancer, primary xenograft, PI3K, drug treatment, mTor</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Aberrant signalling by
phosphatidylinositol-3-kinase (PI3K) is a prominent feature of pancreatic
cancers, due to the high prevalence of abnormalities that regulate this
pathway, including K-ras mutations that occur in approximately 90% of cases,
increased expression of receptor tyrosine kinases like EGFR, and loss of PTEN (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib13">Korc, 1998</a>;
<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib21">Ruggeri <i>et
al</i>, 1998</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib5">Bardeesy and
DePinho, 2002</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib1">Agbunag and
Bar-Sagi, 2004</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib3">Asano <i>et al</i>,
2004</a>; <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib10">Chadha
<i>et al</i>, 2006</a>). The activation of downstream survival signalling
pathways likely has an important role in the aggressive clinical features of
pancreatic cancer, including resistance to chemotherapy. This is supported by
recent results from a randomised clinical trial that showed a modest but
significant improvement in patient survival when the EGFR inhibitor erlotinib
was combined with the standard chemotherapy agent gemcitabine (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib17">Moore <i>et
al</i>, 2007</a>). Furthermore, we have previously shown that treatment with
the natural product wortmannin resulted in decreased PKB/Akt phosphorylation in
an orthotopic xenograft model of pancreas cancer, consistent with PI3K
inhibition, and that combined treatment with wortmannin and gemcitabine
resulted in greater acute induction of apoptosis, and improved tumour growth
inhibition, compared to gemcitabine alone (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib18">Ng <i>et al</i>,
2001</a>).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>NVP-BEZ235 is a novel
imidazoquinoline derivative that shows high selectivity for class I PI3K and
the structurally related mammalian target of rapamycin (mTor; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib15">Maira <i>et
al</i>, 2008</a>). It has pharmacological properties that allow it to be tested
for anticancer effects <i>in vivo</i>, and is well tolerated at dose schedules
that result in decrease phosphorylated levels of the downstream target PKB/Akt.
Furthermore, continuous oral dosing schedules with NVP-BEZ235 are growth
inhibitory in human tumour xenograft mice and rat models (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib15">Maira <i>et
al</i>, 2008</a>).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>In agreement with the experience
from other groups, we have previously shown that primary xenografts can be
established from the majority of pancreatectomy specimens and that when grown
at the orthotopic site, they show typical histological features of pancreatic
cancer (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib19">Ng
<i>et al</i>, 2002</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib20">Rubio-Viqueira
<i>et al</i>, 2006</a>). These tumours therefore offer the opportunity for the
near-clinical testing of novel molecular targeted agents in a controlled
laboratory setting that allows detailed analysis of the relationships between
the tumour characteristics, pharmacological effects, and anticancer activity.
In the present paper we tested the effects of NVP-BEZ235 in a series of five
early passage primary pancreatic cancer xenografts, and show that acute oral
single doses suppress signalling targets downstream from PI3K/mTor in a
time-dependent manner consistent with the pharmacokinetics of the compound, and
that chronic treatment produces significant growth inhibition.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/"
title="Go to other sections in this page">Go to:</a></span></p>

<div style='border:none;border-bottom:solid #97B0C8 1.0pt;padding:0in 0in 0in 0in'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN style='font-size:18.0pt;font-family:"Times New Roman","serif";
text-transform:uppercase'>Materials and methods</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Establishment of
primary pancreatic cancer xenografts </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Animal experiments were carried
out using protocols approved by University Health Network Animal Welfare
Committee. The establishment of the primary pancreatic cancer xenografts was
carried out as previously described (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib19">Ng <i>et al</i>,
2002</a>; <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib29">Yau
<i>et al</i>, 2005</a>). Fresh pancreatic cancer samples that were superfluous
to diagnostic needs were obtained from the University Health Network Tumour
Tissue Bank according to institutional human ethical guidelines. Tumour
fragments were initially implanted subcutaneously into the flanks of male SCID
mice. Primary xenografts established from this material were subsequently
transferred to the orthotopic site of 4- to 5-week-old mice by attaching tumour
pieces from the previous passage to the surface of the exposed pancreas, by a
small incision under general anaesthesia. Five primary pancreatic cancer
xenografts, designated OCIP16, 17, 18, 19, and 21, were used at passage number
46 for these experiments.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Characterisation
of primary xenografts </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Once sufficient tumour tissue was
available, typically at passage number two or three, orthotopic tumours were
rapidly excised and divided into roughly similar pieces. One of these was
processed for protein extraction, one was snap frozen in liquid nitrogen, and
one was fixed in formaldehyde followed by paraffin embedding. Cut tissue
sections were stained with haematoxylin and eosin (H&amp;E) for morphological
assessment, and by immunohistochemistry for relevant protein markers including
surface receptor tyrosine kinases and SMAD4 using appropriate primary
antibodies. Codon 12/13 K-ras mutations were determined by gene sequencing.
Activation of intracellular signalling proteins was assessed by immunohistochemistry
using the following phosphospecific antibodies: Ser473 PKB/Akt; rabbit
monoclonal obtained from Cell Signaling Technology (CST, Danvers, MA, USA);
phosphorylated extracellular-regulated kinase (ERK) 1/2 (mouse monoclonal;
CST). Signal transduction and activator of transcription (Stat) 3, Tyr705
(mouse monoclonal; CST) and Ser727 (rabbit polyclonal; CST). Tumour morphology
was assessed by a pathologist, and the intensity of immunohistochemical
staining for each of the tumour markers was scored from 0 (absent staining) to
3+ (strong staining).</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Drug treatment </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>NVP-BEZ235 (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/figure/fig1/"
target=figure>Figure 1</a>) was obtained from the Oncology Department of the
Novartis Institutes for Biomedical Research in Basel, Switzerland. Fresh stock
solutions of the compound were prepared daily by dissolving in 1 volume of NMP
(1-methyl-2-pyrrolidone; Sigma-Aldrich, Oakville, Ontario, Canada) in a 100C
water bath, then adding 9 volumes of PEG300 (Sigma-Aldrich) to give a final
drug concentration of 12.5&#8201;mg&#8201;ml<sup>&#8722;1</sup>.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/figure/fig1/"
target=figure><span style='font-size:12.0pt;font-family:"Times New Roman","serif";
text-decoration:none'><img border=0 width=100 height=84 id="Picture 13"
src="PMC2676548%20table%201_files/image003.gif" alt="Figure 1"></span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/figure/fig1/"
target=figure>Figure 1</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Structure
of NVP-BEZ235.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>To monitor the acute
pharmacodynamic effects of NVP-BEZ235, five groups each of three randomly
assigned tumour-bearing mice were treated with 50&#8201;mg&#8201;kg<sup>&#8722;1</sup>
NVP-BEZ235 by oral gavage and killed at 0, 2, 4, 8, and 24&#8201;h. The tumours
were rapidly excised and divided into pieces that were snap frozen in liquid
nitrogen, or fixed in formaldehyde and then were paraffin-embedded, or
processed for protein extraction.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>To assess the anticancer effects,
the NVP-BEZ235 dose was reduced to 45&#8201;mg&#8201;kg<sup>&#8722;1</sup>,
q.d., which is a dose and schedule that have been shown to be efficacious in <i>in
vivo</i> mouse xenograft human cancer models (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib15">Maira <i>et
al</i>, 2008</a>). Two groups of 1012 randomly assigned tumour-bearing mice
were treated with NVP-BEZ235 or the vehicle control given by oral gavage daily
for 5 days per week. Treatment commenced when the tumours were just palpable,
and the duration was 35 weeks according the rates of tumour growth for the
different models. The mice were monitored three times weekly by body weight and
abdominal palpation, and for signs of distress, and killed according to animal
welfare guidelines if they showed &gt;10% loss of body weight or other signs of
significant distress due to tumour growth or treatment toxicity. At the end of
treatment the animals were killed and the tumours were harvested and weighed
after removal of non-tumoural tissues. The tumours were then processed for
further analysis, similar to the acute single-dose series.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Measurement of
NVP-BEZ235 effects </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>The pharmacodynamic effects of
acute single doses were investigated by western blot and ELISA analyses of the
tumour lysates. Minced tumour pieces were homogenised in 1&#8201;ml lysis
buffer (50&#8201;mmol&#8201;l<sup>&#8722;1</sup> HEPES (pH 8.0), 10% glycerol,
1% Triton X-100, 150&#8201;mmol&#8201;l<sup>&#8722;1</sup> NaCl,
1&#8201;mmol&#8201;l<sup>&#8722;1</sup> EDTA, 1.5&#8201;mmol&#8201;l<sup>&#8722;1</sup>
MgCl<sub>2</sub>, 100&#8201;mmol&#8201;l<sup>&#8722;1</sup> NaF,
10&#8201;mmol&#8201;l<sup>&#8722;1</sup> NaP<sub>2</sub>O<sub>7</sub>H<sub>2</sub>O,
1&#8201;mmol&#8201;l<sup>&#8722;1</sup> NaVO<sub>4</sub>) containing protease
inhibitor cocktail tablets (Roche Canada, Mississauga, Ontario, Canada) for
1&#8201;h on ice. Homogenates were clarified by centrifuging at
14&#8201;000&#8201;r.p.m. at 4C for 15&#8201;min. Samples were then heated in
sample buffer for 10&#8201;min at 95C, run on 10% SDSpolyacrylamide gels, and
transferred to PVDF membranes using the Mini Trans-Blot Electrophoresis
Transfer Cell (Bio-Rad Laboratories, Mississauga, Ontario, Canada). Membrane
blots were blocked for 1&#8201;h at room temperature with 10% BSA in TBS with
1% Tween 20 and then incubated overnight at 4C with the following primary
phosphospecific antibodies: Ser473 PKB/Akt (rabbit monoclonal from CST,
1&#8201;:&#8201;500 dilution), Ser21/9 GSK3 <i>&#945;</i>/<i>&#946;</i> (rabbit
polyclonal from CST, 1&#8201;:&#8201;1000), Ser235/236 S6 ribosomal protein
(CST; 1&#8201;:&#8201;7000) and Ser240/244 S6 ribosomal protein (rabbit
polyclonal (CST; 1&#8201;:&#8201;1000), Thr37/46 4E-BP-1 (CST;
1&#8201;:&#8201;1000), Ser727 Stat3 (CST; 1&#8201;:&#8201;1000), and Tyr705
Stat3 (CST; 1&#8201;:&#8201;1000). The loading control was anti-actin
(1&#8201;:&#8201;7000; Abcam, Cambridge, MA, USA). Following overnight
incubation with the primary antibody, the blots were probed with either
anti-rabbit polyclonal or anti-mouse monoclonal secondary antibodies labelled
with horseradish peroxidase (GE Healthcare Biosciences Inc. Baie d'Urfe, Quebec,
Canada) and then exposed to SuperSignal West Pico Chemiluminescent Substrate
(Fisher Scientific, Ottawa, Ontario, Canada) according to the manufacturer's
instructions.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>To assess the effects of chronic
drug administration on angiogenesis, proliferation, and apoptosis,
paraffin-embedded sections of tumour tissues were stained by
immunohistochemistry using antibodies to CD31, cyclin D1, p27, and cleaved
caspase 3. The slides were then scanned using a ScanScope CS (Aperio
Technologies Inc., Vista, CA, USA). Digital image analysis was carried out
using the Aperio software, based on 10 fields of view of the tumoural area for
each section, at  10 magnification.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Analytical
procedure for quantification of BEZ235 </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Quantitative analysis of tumour
samples for BEZ235 was performed with an HPLC/dual mass spectrometry (MS/MS)
method. To each gram of tissue 1&#8201;ml of phosphate-buffered saline was
added. The tissues were homogenised using an ULTRA-TURRAX (TP18-10; IKA,
Staufen, Germany) homogeniser, keeping the material during the homogenisation
as cold as possible by returning the homogenate to an ice bath between short
(approximately 15&#8201;s) bursts. Proteins in tissue homogenate were
precipitated by the addition of an equal volume of acetonitrile and processed
further for chromatographic separation as described below. Stock solutions of
the analyte BEZ235 (MW 469.6) and the structurally related internal standard
(IS, MW 476.6) were prepared fresh daily at a concentration of 10&#8201;<i>&#956;</i>g&#8201;ml<sup>&#8722;1</sup>
(analyte) and 1&#8201;<i>&#956;</i>g&#8201;ml<sup>&#8722;1</sup> (IS) in
methanol/water (2&#8201;:&#8201;9, v/v). Further dilutions were prepared in the
same solvent. Calibration samples were prepared in pooled homogenates of the
corresponding tumours obtained from untreated animals. Tumour homogenate
(25&#8201;<i>&#956;</i>l) was mixed with appropriate amounts of BEZ235 to
deliver a nominal final concentration of 102000&#8201;ng&#8201;ml<sup>&#8722;1</sup>.
The quality control (QC) samples were spiked with the analytes to give a final
concentration of nominally 40, 100, 400, and 1600&#8201;ng&#8201;ml<sup>&#8722;1</sup>
respectively. A 50&#8201;<i>&#956;</i>l aliquot (1&#8201;<i>&#956;</i>g&#8201;ml<sup>&#8722;1</sup>)
of the IS was added to each calibration standard and to the QC samples and
mixed on a vortex mixer for 15&#8201;s. After three times repeated protein
precipitation by addition of an equal volume of acetonitrile followed by
evaporation to dryness, the samples were re-dissolved in 100&#8201;<i>&#956;</i>l
acetonitrile/water (1&#8201;:&#8201;9, v/v) containing 0.2% v/v formic acid.
Sample injection volume was 5&#8201;<i>&#956;</i>l for the chromatographic
separation.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>The liquid chromatographic
separations were carried out using an Agilent 1100 Series (Agilent, Palo Alto,
CA, USA) HPLC system with vacuum degasser, capillary pump, and thermostated
column compartment (40C) combined with an automated injection device (CTC-PAL;
CTC Analytics, Zwingen, Switzerland). As chromatographic separation matrix a RESECT
Ultra Cyano reverse-phase HPLC column (column size 50  1&#8201;mm, particle
size 3&#8201;<i>&#956;</i>m, preceded by a guard column: Phenomenex AJO-4304
phenylpropyl, size 4  2&#8201;mm) was used. Gradient mobile programming was
used with a flow rate 60&#8201;<i>&#956;</i>l&#8201;min<sup>&#8722;1</sup>; the
mobile phase consisted of acetonitrile and 0.2% formic acid in water
(95&#8201;:&#8201;5). The column eluent was directly introduced into the ion
source of the triple quadrupole mass spectrometer Quattro Micro (Micromass,
Manchester, UK) controlled by MassLynx 4.0 software. Electrospray positive
ionisation (ESI(+)) multiple reaction monitoring was used for the MS/MS
detection of BEZ235. After ESI(+) ionisation, the molecularproduct transitions
(<i>m/z</i> 470.35 &#8594; 443.25 product ion for BEZ235 and <i>m/z</i> 477.45
&#8594; 477.30 product ion for the IS) were monitored for the analyte and IS
respectively. The calibration curve was prepared by adding the structurally
related IS and appropriate amounts of analyte to mouse plasma or tumour tissue
extract, covering a range from 2 to 2000&#8201;ng&#8201;ml<sup>&#8722;1</sup>
with LOQ set to 10&#8201;ng&#8201;ml<sup>&#8722;1</sup> for plasma and
50&#8201;ng&#8201;g<sup>&#8722;1</sup> for the tumour tissue respectively (CV
and overall bias less than 30%). Regression analysis was performed using
QuanLynx 4.0 (Micromass) and Excel 2002 (Microsoft). Concentrations of unknown
samples were calculated from the peak area ratio of the daughter ion of the
analyte to the daughter ion of its IS (ordinate) against the nominal
concentration (abscissa). Assay linearity was indicated by an overall
regression coefficient of 0.9981.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Statistics </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>All values are presented as
means.e. Comparisons between two groups (control <i>vs</i> NVP-BEZ235) were
achieved using the two-tailed Student's <i>t</i>-test. The criterion for
statistical significance was <i>P</i>&lt;0.05.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/"
title="Go to other sections in this page">Go to:</a></span></p>

<div style='border:none;border-bottom:solid #97B0C8 1.0pt;padding:0in 0in 0in 0in'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN style='font-size:18.0pt;font-family:"Times New Roman","serif";
text-transform:uppercase'>Results</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Characterisation
of orthotopic primary pancreatic cancer xenografts </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Histological examination of the
H&amp;E sections showed that the primary xenografts were adenocarcinomas with
features similar to the original surgical specimens, with the exception of
OIP17 that grew as sheets of poorly differentiated cancer cells. As seen in <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/figure/fig2/"
target=figure>Figure 2</a>, the histological features were more complex than
those typically seen in xenografts established at the subcutaneous site from
cell lines, as has been previously noted (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib20">Rubio-Viqueira
<i>et al</i>, 2006</a>). The tumours tended to be moderately well
differentiated, with mucin production. They were organised into glandular
structures, with a prominent fibrovascular stroma that in some cases comprised
the bulk of the tumour. Cellular DNA content analysis by flow cytometry
confirmed that in many of these tumours normal mouse cells accounted for
&gt;80% of the total cell population. By immunohistochemistry, phosphorylated
Akt was readily detected in all five models (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/figure/fig2/"
target=figure>Figure 2</a>). Staining for Ser473 Akt was also observed in the
stroma of some of the xenografts, but this was less intense that seen in the
tumour tissue. Immunohistochemical staining for the various growth factor
receptors showed prominent surface membrane staining for EGFR in most cases,
and variable expression of HER2 (ErbB2), c-Met (HGFR), and IGF-1R, often with
marked intra-tumoural heterogeneity in staining intensity. <span
style='background:yellow'>The characteristics of the primary xenografts are
summarised in <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/table/tbl1/"
target=true>Table 1</a>.</span></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/figure/fig2/"
target=figure><span style='font-size:12.0pt;font-family:"Times New Roman","serif";
text-decoration:none'><img border=0 width=100 height=127 id="Picture 12"
src="PMC2676548%20table%201_files/image004.gif" alt="Figure 2"></span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/figure/fig2/"
target=figure>Figure 2</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Histological
sections of the orthotopically grown primary pancreatic cancer xenografts
stained with haematoxylin and eosin (H&amp;E; right panels), and by immunohistochemistry
using anti-Ser473 Akt (left panels). Scale bar in the top left panel=500&#8201;
<b>...</b></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/table/tbl1/"
target=table><span style='font-size:12.0pt;font-family:"Times New Roman","serif";
text-decoration:none'><img border=0 width=204 height=140 id="Picture 11"
src="PMC2676548%20table%201_files/image005.png" alt="Table 1"></span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/table/tbl1/"
target=table>Table 1</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
background:yellow'>Characterisation of the primary pancreatic cancer xenografts</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Acute
single-dose effects of NVP-BEZ235 </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>The acute single dose of
50&#8201;mg&#8201;kg<sup>&#8722;1</sup> NVP-BEZ235 administered by oral gavage
was well tolerated. The levels of Ser473 phosphorylated PKB/Akt measured by
ELISA showed considerable inter-tumoural heterogeneity, which reflects the
complex nature of these tumours relative to subcutaneous implants of cell
lines, but there was an obvious decrease in the mean values in all five models
at 2&#8201;h, followed by recovery over 24&#8201;h (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/figure/fig3/"
target=figure>Figure 3</a>). We also observed a decrease in Ser9/21GSK3<i>&#945;</i>/<i>&#946;</i>
levels by western blot that followed a similar time course to p-Akt (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/figure/fig4/"
target=figure>Figure 4</a>), consistent with inhibition of the PI3K/Akt pathway
by NVP-BEZ235 in these models. We also found a time-dependent suppression of
the downstream mTor targets Ser235/236 S6 ribosomal protein and Thr37/46 4E-BP1
in all five models, consistent with the action of NVP-BEZ235 as a dual PI3K and
mTor inhibitor. Similar to the ELISA data shown in <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/figure/fig3/"
target=figure>Figure 3</a>, we observed considerable inter-tumoural
heterogeneity within the triplicate samples, which to some extent tracked
differences in the total protein levels, as shown in <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#sup1">Supplementary
Figure 1</a>. Phosphorylated Stat3 was readily detected in all five models,
consistent with previous reports showing aberrant activation in pancreatic
cancer cells (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib11">DeArmond <i>et
al</i>, 2003</a>), but there was no significant decrease in the levels
following treatment with NVP-BEZ235 (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/figure/fig4/"
target=figure>Figure 4</a>), suggesting that the mechanisms of Stat3 activation
are largely independent of PI3K signalling.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/figure/fig3/"
target=figure><span style='font-size:12.0pt;font-family:"Times New Roman","serif";
text-decoration:none'><img border=0 width=100 height=99 id="Picture 10"
src="PMC2676548%20table%201_files/image006.gif" alt="Figure 3"></span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/figure/fig3/"
target=figure>Figure 3</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Effects
of acute single doses of NVP-BEZ235 on phosphorylated Akt measured using an
ELISA technique (10&#8201;<i>&#956;</i>g total protein per 50&#8201;<i>&#956;</i>l
well). Groups of animals bearing the five primary xenografts at the orthotopic
site were <b>...</b></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/figure/fig4/"
target=figure><span style='font-size:12.0pt;font-family:"Times New Roman","serif";
text-decoration:none'><img border=0 width=100 height=183 id="Picture 9"
src="PMC2676548%20table%201_files/image007.gif" alt="Figure 4"></span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/figure/fig4/"
target=figure>Figure 4</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Western
blots of tumour lysates obtained from triplicate primary xenografts at the
indicated time points following an acute single dose of NVP-BEZ235,
50&#8201;mg&#8201;kg<sup>&#8722;1</sup>, probed with primary antibodies to:
Ser473 Akt, Ser21/9 GSK3<i>&#945;</i> <b>...</b></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Tumour concentrations of
NVP-BEZ235 were measured in all of the acute single-dose samples with the
exception of OCIP19, where insufficient material was available due to their
small size. Drug concentrations were found to be in average higher at 2&#8201;h
than 24&#8201;h after administration (1.01 <i>vs</i> 0, 28.4 <i>vs</i> 0.50,
5.5 <i>vs</i> 1.44, 2.1 <i>vs</i> 1.20&#8201;nmol&#8201;g<sup>&#8722;1</sup>,
for OCIP16, 18, 17, and 21 respectively; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/figure/fig4/"
target=figure>Figure 4</a>). These data show that different maximum
concentrations are achieved in the four models but that in all cases, the
compound is cleared form the tumour tissue with time, in agreement with the
reported mouse pharmacokinetic profile (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib15">Maira <i>et
al</i>, 2008</a>).</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Tumour growth
inhibition by NVP-BEZ235 treatment </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Daily oral administration of
NVP-BEZ235 at a dose of 45&#8201;mg&#8201;kg<sup>&#8722;1</sup> was well
tolerated in the tumour-bearing mice. Loss of weight occurred in the control
groups of OCIP16 and 17, which was presumably the effect of the tumours, but
the other groups of animals maintained their weight during the course of
treatment and there were no statistically significant differences in the body
weights of treated and control animals at the end of treatment in any of the
five groups (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/figure/fig5/"
target=figure>Figure 5</a>). Because of the location of the tumour in the
orthotopic pancreas site, the tumour size was not measured until the end of the
experiments when the animals were killed 2&#8201;h after the final dose.
Consequently, at the end of the 3- to 5-week treatment, orthotopic tumours were
dissected free of surrounding normal tissues and weighed. As shown in <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/figure/fig6/"
target=figure>Figure 6</a>, NVP-BEZ235 treatment of tumour models OCIP16, 17,
and 21 resulted in statistically significant delay in tumour growth (56, 36,
and 46% respectively) when compared with vehicle-treated controls. A fourth
model, OCIP19, also showed growth inhibition, but this effect did not reach
statistical significance, whereas there was no significant growth inhibition in
OCIP18. By western blot, phosphorylated Akt and S6 were readily detected in
these tumours excised 2&#8201;h after the final dose of NVP-BEZ235 (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/figure/fig7/"
target=figure>Figure 7</a>), although it should be noted that the sample
processing was considerably longer than that for the acute time course
experiment shown in <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/figure/fig4/"
target=figure>Figure 4</a>, which might have affected these results. Compound
concentrations in the tumour tissue 2&#8201;h after last treatment were in
average of 1.11, 1.30, 0.81, and 1.16&#8201;nmol&#8201;g<sup>&#8722;1</sup>,
for OCIP16, 18, 17, and 21 respectively. Hence the lack of efficacy observed in
the model OCIP18 cannot be accounted for by a lack of exposure. NVP-BEZ235 did
not show accumulation over time in all the four tumour models tested, arguing
that the efficacy is likely due to similar effects observed after a single-dose
administration.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/figure/fig5/"
target=figure><span style='font-size:12.0pt;font-family:"Times New Roman","serif";
text-decoration:none'><img border=0 width=100 height=115 id="Picture 8"
src="PMC2676548%20table%201_files/image008.gif" alt="Figure 5"></span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/figure/fig5/"
target=figure>Figure 5</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Animal
weights during chronic administration of NVP-BEZ235 or vehicle control.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/figure/fig6/"
target=figure><span style='font-size:12.0pt;font-family:"Times New Roman","serif";
text-decoration:none'><img border=0 width=100 height=108 id="Picture 7"
src="PMC2676548%20table%201_files/image009.gif" alt="Figure 6"></span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/figure/fig6/"
target=figure>Figure 6</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Tumour
weights at the completion of chronic dose administration. Horizontal lines
indicate the mean value for each group.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/figure/fig7/"
target=figure><span style='font-size:12.0pt;font-family:"Times New Roman","serif";
text-decoration:none'><img border=0 width=100 height=152 id="Picture 6"
src="PMC2676548%20table%201_files/image010.gif" alt="Figure 7"></span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/figure/fig7/"
target=figure>Figure 7</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Western
blots of tumour lysates obtained 2&#8201;h after the final dose of NVP-BEZ235
in the chronic dosing groups of animals, probed for Ser473 Akt and Ser235/236
and Ser240/244 S6 ribosomal protein, with actin loading controls. Owing to
their small <b>...</b></span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Effects of
NVP-BEZ235 on proliferation, apoptosis, and angiogenesis markers </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>To investigate the mechanisms of
tumour growth inhibition by NVP-BEZ235, the tumours were labelled for cleaved
caspase 3 and the proliferation markers cyclin D1 and p27 by
immunohistochemistry, and the staining intensities were measured using
semi-automated image analysis protocols. Cleaved caspase 3 showed low levels of
staining relative to that previously observed by us in xenografts established
from cell lines, and there was no significant increase in staining in any of
the primary xenograft groups treated with NVP-BEZ235. There was a trend towards
reduced labelling for cyclin D1 in the NVP-BEZ235-treated groups (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/figure/fig8/"
target=figure>Figure 8</a>), and this was statistically significant in OCIP17,
19, and 21, whereas in the non-responsive OCIP18 model there was a
non-significant increase in cyclin D1 in the NVP-BEZ235-treated animals. No
significant effects on p27 were seen in any of the five primary xenograft
models. Examination of newly formed blood vessels using CD31 staining showed
that these were substantially present in the surrounding fibrovascular stroma,
rather than invading into tumour masses. We tested several image analysis
routines based on the number of CD31-stained blood vessels, their size, and
distribution within tumour tissue and stroma. However, none of these yielded
significant changes in patterns of blood vessel formation in any of the
drug-treated tumours, relative to the vehicle controls.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/figure/fig8/"
target=figure><span style='font-size:12.0pt;font-family:"Times New Roman","serif";
text-decoration:none'><img border=0 width=100 height=90 id="Picture 5"
src="PMC2676548%20table%201_files/image011.gif" alt="Figure 8"></span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/figure/fig8/"
target=figure>Figure 8</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Cyclin
D1 levels in tumour tissue following chronic dosing with NVP-BEZ235 or drug
vehicle, measured using immunohistochemistry and semi-quantitative image
analysis. Plots show the per cent labelled areas for individual tumours and the
mean values, together <b>...</b></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/"
title="Go to other sections in this page">Go to:</a></span></p>

<div style='border:none;border-bottom:solid #97B0C8 1.0pt;padding:0in 0in 0in 0in'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN style='font-size:18.0pt;font-family:"Times New Roman","serif";
text-transform:uppercase'>Discussion</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>The importance of aberrant PI3K
signalling in cancer has been recognised for many years (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib12">Hennessy <i>et
al</i>, 2005</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib27">Woodgett,
2005</a>; <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib26">Vogt
<i>et al</i>, 2006</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib28">Workman <i>et
al</i>, 2006</a>). Apart from promoting cell growth, several signalling
pathways diverge downstream from activated PKB/Akt that suppresses apoptosis.
The enhancement of cell survival by PI3K signalling probably has a major
function during early cancer development, and has also been linked to the high
levels drug and radiation resistance seen in patients with pancreatic cancer (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib18">Ng <i>et al</i>,
2001</a>; <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib6">Bondar
<i>et al</i>, 2002</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib14">Mackenzie,
2004</a>; <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib8">Brunner
<i>et al</i>, 2005</a>), although it should be noted that pancreatic cancers
are heterogeneous, and the activation of additional signalling elements,
including Stat3, NF&#954;B, and hedgehog pathway, is also likely to be an
important determinant of biological aggression (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib5">Bardeesy and
DePinho, 2002</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib2">Arlt <i>et al</i>,
2003</a>; <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib11">DeArmond
<i>et al</i>, 2003</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib25">Thayer <i>et
al</i>, 2003</a>). Experimental PI3K inhibitors can sensitise resistant cancer
cells to cytotoxic agents or radiation, suggesting therapeutic potential in the
clinic, but until recently <i>in vivo</i> testing was limited due to their
toxicity or poor pharmacological properties. In contrast, the novel agent
NVP-BEZ235 has suitable drug-like properties, and is currently been tested in
phase I clinical trials in cancer patients. Given the high prevalence of
genetic changes that can drive PI3K signalling in pancreatic cancers, we
examined the pharmacodynamic and anticancer effects of NVP-BEZ235 in a series
of five recently established primary pancreatic cancer xenografts.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Primary xenografts can be
established in immune-deprived mice from the majority of pancreatic cancer
resections. Particularly when grown at the orthotopic site, they show growth
patterns including the formation of glandular structures embedded in a dense
fibrovascular stroma that strikingly resemble those seen in surgical samples (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib9">Capella <i>et
al</i>, 1999</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib19">Ng <i>et al</i>,
2002</a>; <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib20">Rubio-Viqueira
<i>et al</i>, 2006</a>). These tumours therefore appear to provide a realistic
laboratory setting in which to test novel agents for treating a clinically
intractable problem. In all models tested, acute single doses of NVP-BEZ235
decreased the phosphorylation of PKB/Akt, as well as its immediate downstream
target GSK3, with maximum inhibition at the 2&#8201;h time point followed by
recovery at 24&#8201;h, consistent with the pharmacokinetics of this compound (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib15">Maira <i>et
al</i>, 2008</a>). These findings confirm that NVP-BEZ235 is able to inhibit
the activation of downstream PI3K effectors <i>in vivo</i>. In addition to its
activity against class I PI3K, and like other PI3K inhibitors, such as
wortmannin and LY294002 (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib7">Brunn <i>et al</i>,
1996</a>), NVP-BEZ235 also blocks the catalytic activity of mTor. The kinase
domain of this serine/threonine kinase has a high sequence similarity to PI3K.
We observed decreases in the phosphorylation of downstream mTor targets,
particularly the S6 ribosomal protein, that showed a similar time course to
that seen with PKB/Akt phosphorylation. These findings suggest that mTor
inhibition occurs <i>in vivo</i> at drug concentrations comparable to those
that inhibit PI3K.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>We tested for anticancer effects
of NVP-BEZ235 using daily oral dosing, which is similar to treatment schedules
commonly used in clinical trials testing novel molecular targeted agents. The
primary end points for this part of the study were animal body and the tumour
weight at the end of the treatment period. The tumour-bearing mice were also
monitored by abdominal palpation, which gave a rough indication of tumour
growth. In a pilot study we found that at a daily dose of 45&#8201;mg&#8201;kg<sup>&#8722;1</sup>
NVP-BEZ235 was well tolerated by the SCID mice used for the xenografts, although
weight loss occurred with more intensive treatment. This finding is consistent
with previously reported <i>in vivo</i> efficacy studies from the Novartis
group (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib24">Stauffer
<i>et al</i>, 2007</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib15">Maira <i>et
al</i>, 2008</a>). Using the 45&#8201;mg&#8201;kg<sup>&#8722;1</sup> daily for
5 days per week dose schedule, we did not see increased toxicity relative to
the drug vehicle control group during the treatment period. In three of the
five primary xenografts, we observed statistically significant reduction in the
tumour size or weight relative to the drug vehicle control group, which was
consistent with the impression obtained from abdominal palpation that oral
daily treatment with NVP-BEZ235 inhibited tumour growth. Non-significant growth
inhibition was also seen in a fourth primary xenograft, OCIP19. This produced
small, slow-growing tumours, and a statistically significant effect might have
been lost due to measurement error. A fifth model, OCIP18, was insensitive to
growth inhibition by NVP-BEZ235. Because the acute effects on PKB/Akt
phosphorylation were comparable to those seen with the other primary
xenografts, the lack of response to NVP-BEZ235 treatment is likely explained by
the activity of additional oncogenic signalling pathways in OCIP18, rather than
failure to inhibit the drug target. Perhaps relevant to this, the levels of
cyclin D1, which can be regulated by several mechanisms downstream of PI3K/mTor,
showed a decrease in all models with the exception of OCIP18 (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/figure/fig8/"
target=figure>Figure 8</a>).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>It is likely that the use of
orthotopically grown early passage primary xenografts provides a better
prediction of clinical activity, relative to <i>in vivo</i> sensitivity testing
based on pancreatic cancer cell lines. Overall, the effects of NVP-BEZ235
appear less dramatic in these models relative to those seen in xenograft
established from cell lines (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib15">Maira <i>et
al</i>, 2008</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib23">Serra <i>et
al</i>, 2008</a>), which are typically poorly differentiated and rapidly
proliferating. We also failed to show significant anti-angiogenic effects in
the orthotopic primary pancreatic cancer xenografts, which is in contrast with
other groups who have reported pronounced anti-angiogenic effects by mTor
inhibitors used to treat xenografts established from pancreatic cancer cell
lines (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib4">Azzariti
<i>et al</i>, 2008</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib16">Manegold <i>et
al</i>, 2008</a>). Again, we feel that this might reflect differences in the
growth patterns seen using the orthotopic primary xenografts. Interestingly, <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib22">Schnell <i>et
al</i> (2008)</a> have recently shown that NVP-BEZ235 inhibited microvessel
permeability in a syngeneic rat mammary carcinoma model, but we did not test
for this effect in the present study. Nevertheless, the response rate of 3/5
seen in the present study appears greater than that recently reported for other
molecular targeted agents in primary pancreatic cancer xenografts (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib20">Rubio-Viqueira
<i>et al</i>, 2006</a>), suggesting that dual PI3K/mTor inhibitors like NVP-BEZ235
might have useful anticancer effects in pancreatic cancer patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>It remains to be determined if
the daily oral dosing schedule for NVP-BEZ235 used in this study will be
optimal in the clinic. Results from <i>in vitro</i> experiments suggest that
the anticancer effects of PI3K inhibitors are dependant on the extent and
duration of target inhibition. However, the acute single-dose experiments
showed that the NVP-BEZ235 dose used did not completely inhibit PKB/Akt in
tumour tissue, and the effect was of relatively short duration. Furthermore,
phosphorylated PKB/Akt was detectable in the tumour samples obtained 2&#8201;h
after the final dose in the chronic treatment group, indicating incomplete drug
target inhibition. It is unlikely that complete target inhibition could be
sustained over long periods in animal models or cancer patients, because PI3K
signalling is critical in the maintenance of normal tissues. However, it is
possible that higher doses given intermittently might give a better therapeutic
ratio by producing more complete PI3K inhibition in the tumour, while allowing
time for normal tissue recovery.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>An alternative strategy would be
to combine a PI3K inhibitor like NVP-BEZ235 with other anticancer agents. For
example, we have previously shown that this can markedly enhance sensitivity to
the standard agent gemcitabine when used in an intermittent dose schedule (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#bib18">Ng <i>et al</i>,
2001</a>). However, in the longer term it is likely that synergistic
interactions could be obtained combining PI3K inhibitors with agents targeting
other signalling pathways that are aberrantly regulated in pancreatic cancers.
The clinical development of treatment protocols incorporating multiple
molecular targeted agents is problematic, because the optimum combination would
depend on the specific pattern abnormalities in a particular cancer patient.
Hence we believe that the long-term strategy needed for an intractable problem
such as pancreatic cancer requires closer integration between basic science and
clinical oncology, including the preclinical testing based on models similar to
those used in the present study.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/"
title="Go to other sections in this page">Go to:</a></span></p>

<div style='border:none;border-bottom:solid #97B0C8 1.0pt;padding:0in 0in 0in 0in'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN style='font-size:18.0pt;font-family:"Times New Roman","serif";
text-transform:uppercase'>Supplementary Material</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><b><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Supplementary
Figure 1:</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/bin/6604995x1.tif">Click
here for supplemental data</a><sup>(2.6M, tif)</sup></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><b><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Supplementary
Figure Legend:</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/bin/6604995x2.doc">Click
here for supplemental data</a><sup>(20K, doc)</sup></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/"
title="Go to other sections in this page">Go to:</a></span></p>

<div style='border:none;border-bottom:solid #97B0C8 1.0pt;padding:0in 0in 0in 0in'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN style='font-size:18.0pt;font-family:"Times New Roman","serif";
text-transform:uppercase'>Acknowledgments</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>We thank Dr Steven Gallinger and
Dr Ming Tsao for their help establishing the primary pancreatic cancer
xenografts, and past and present members of the Hedley Lab, particularly Drs
Nhu-An Pham and Diana Birle for their helpful comments. Joao Magalhaes was
responsible for the pathological examination of the primary xenografts, and we
thank him, and James Ho May Cheung, and Trudey Nicklee for their excellent
technical help with the immunohistochemistry staining and digital image
analysis.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Grant support</span></i><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>:
National Cancer Institute of Canada/Canadian Cancer Society.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/"
title="Go to other sections in this page">Go to:</a></span></p>

<div style='border:none;border-bottom:solid #97B0C8 1.0pt;padding:0in 0in 0in 0in'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN style='font-size:18.0pt;font-family:"Times New Roman","serif";
text-transform:uppercase'>Notes</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#sup1">Supplementary
Information</a> accompanies the paper on British Journal of Cancer website (<a
href="http://www.nature.com/bjc" target="pmc_ext">http://www.nature.com/bjc</a>)</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/"
title="Go to other sections in this page">Go to:</a></span></p>

<div style='border:none;border-bottom:solid #97B0C8 1.0pt;padding:0in 0in 0in 0in'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN style='font-size:18.0pt;font-family:"Times New Roman","serif";
text-transform:uppercase'>References</span></b></p>

</div>

<ul type=disc>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Agbunag C, Bar-Sagi D.
     Oncogenic K-ras drives cell cycle progression and phenotypic conversion of
     primary pancreatic duct epithelial cells. Cancer Res. 2004;64:56595663. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/15313904" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Arlt A, Gehrz A, Muerkoster
     S, Vorndamm J, Kruse ML, Folsch UR, Schafer H. Role of NF-kappaB and
     Akt/PI3K in the resistance of pancreatic carcinoma cell lines against
     gemcitabine-induced cell death. Oncogene. 2003;22:32433251. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/12761494" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Asano T, Yao Y, Zhu J, Li D,
     Abbruzzese JL, Reddy SA. The PI3-kinase/Akt signaling pathway is activated
     due to aberrant Pten expression and targets transcription factors
     NF-kappaB and c-Myc in pancreatic cancer cells 4. Oncogene. 2004;23:85718580.
     [<a href="http://www.ncbi.nlm.nih.gov/pubmed/15467756" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Azzariti A, Porcelli L,
     Gatti G, Nicolin A, Paradiso A. Synergic antiproliferative and
     antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer
     cells. Biochem Pharmacol. 2008;75:10351044. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/18191814" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Bardeesy N, DePinho RA.
     Pancreatic cancer biology and genetics. Nat Rev Cancer. 2002;2:897909. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/12459728" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Bondar VM, Sweeney-Gotsch B,
     Andreeff M, Mills GB, McConkey DJ. Inhibition of the phosphatidylinositol
     3&#8242;-kinase-AKT pathway induces apoptosis in pancreatic carcinoma
     cells <i>in vitro</i> and <i>in vivo</i>. Mol Cancer Ther. 2002;1:989997.
     [<a href="http://www.ncbi.nlm.nih.gov/pubmed/12481421" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Brunn GJ, Williams J, Sabers
     C, Wiederrecht G, Lawrence JC, Jr, Abraham RT. Direct inhibition of the
     signaling functions of the mammalian target of rapamycin by the
     phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J. 1996;15:52565267.
     [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC452270/">PMC free
     article</a>] [<a href="http://www.ncbi.nlm.nih.gov/pubmed/8895571"
     target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Brunner TB, Cengel KA, Hahn
     SM, Wu J, Fraker DL, McKenna WG, Bernhard EJ. Pancreatic cancer cell
     radiation survival and prenyltransferase inhibition: the role of K-Ras 2. Cancer
     Res. 2005;65:84338441. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/16166322" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Capella G, Farre L,
     Villanueva A, Reyes G, Garcia C, Tarafa G, Lluis F. Orthotopic models of
     human pancreatic cancer. Ann NY Acad Sci. 1999;880:103109. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/10415855" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Chadha KS, Khoury T, Yu J,
     Black JD, Gibbs JF, Kuvshinoff BW, Tan D, Brattain MG, Javle MM. Activated
     Akt and Erk expression and survival after surgery in pancreatic carcinoma
     1. Ann Surg Oncol. 2006;13:933939. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/16788754" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>DeArmond D, Brattain MG,
     Jessup JM, Kreisberg J, Malik S, Zhao S, Freeman JW. Autocrine-mediated
     ErbB-2 kinase activation of STAT3 is required for growth factor
     independence of pancreatic cancer cell lines. Oncogene. 2003;22:77817795.
     [<a href="http://www.ncbi.nlm.nih.gov/pubmed/14586404" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Hennessy BT, Smith DL, Ram
     PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug
     discovery 12. Nat Rev Drug Discov. 2005;4:9881004. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/16341064" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Korc M. Role of growth
     factors in pancreatic cancer. Surg Oncol Clin N Am. 1998;7:2541. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/9443985" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Mackenzie MJ. Molecular
     therapy in pancreatic adenocarcinoma 2. Lancet Oncol. 2004;5:541549. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/15337483" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Maira SM, Stauffer F,
     Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De PA,
     Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers
     W, Garcia-Echeverria C. Identification and characterization of NVP-BEZ235,
     a new orally available dual phosphatidylinositol 3-kinase/mammalian target
     of rapamycin inhibitor with potent <i>in vivo</i> antitumor activity. Mol
     Cancer Ther. 2008;7:18511863. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/18606717" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Manegold PC, Paringer C,
     Kulka U, Krimmel K, Eichhorn ME, Wilkowski R, Jauch KW, Guba M, Bruns CJ.
     Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001
     (Everolimus) increases radiosensitivity in solid cancer. Clin Cancer Res. 2008;14:892900.
     [<a href="http://www.ncbi.nlm.nih.gov/pubmed/18245553" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Moore MJ, Goldstein D, Hamm
     J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA,
     Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M,
     Parulekar W. Erlotinib plus gemcitabine compared with gemcitabine alone in
     patients with advanced pancreatic cancer: a phase III trial of the
     National Cancer Institute of Canada Clinical Trials Group 2. J Clin Oncol.
     2007;25:19601966. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/17452677"
     target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Ng SS, Tsao MS, Nicklee T,
     Hedley DW. Wortmannin inhibits pkb/akt phosphorylation and promotes
     gemcitabine antitumor activity in orthotopic human pancreatic cancer
     xenografts in immunodeficient mice. Clin Cancer Res. 2001;7:32693275. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/11595724" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Ng SS, Tsao MS, Nicklee T,
     Hedley DW. Effects of the epidermal growth factor receptor inhibitor
     OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human
     pancreatic adenocarcinoma. Mol Cancer Ther. 2002;1:777783. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/12492110" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Rubio-Viqueira B, Jimeno A,
     Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C, Shi C, Danenberg K,
     Danenberg PV, Kuramochi H, Tanaka K, Singh S, Salimi-Moosavi H, Bouraoud
     N, Amador ML, Altiok S, Kulesza P, Yeo C, Messersmith W, Eshleman J,
     Hruban RH, Maitra A, Hidalgo M. An <i>in vivo</i> platform for
     translational drug development in pancreatic cancer 5. Clin Cancer Res. 2006;12:46524661.
     [<a href="http://www.ncbi.nlm.nih.gov/pubmed/16899615" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Ruggeri BA, Huang L, Wood M,
     Cheng JQ, Testa JR. Amplification and overexpression of the AKT2 oncogene
     in a subset of human pancreatic ductal adenocarcinomas 17. Mol Carcinog. 1998;21:8186.
     [<a href="http://www.ncbi.nlm.nih.gov/pubmed/9496907" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Schnell CR, Stauffer F, Allegrini
     PR, O'Reilly T, McSheehy PM, Dartois C, Stumm M, Cozens R,
     Littlewood-Evans A, Garcia-Echeverria C, Maira SM. Effects of the dual
     phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor
     NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer
     Res. 2008;68:65986607. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/18701483" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Serra V, Markman B,
     Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori
     F, Di CS, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J.
     NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and
     inhibits the growth of cancer cells with activating PI3K mutations. Cancer
     Res. 2008;68:80228030. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/18829560" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Stauffer F,
     Garcia-Echeverria C, Furet P, Schnell C, Ruetz S, Maira M, Fritsch CM. Biochemical,
     cellular and <i>in vivo</i> profiling of a new PI3K inhibitor from the
     imidazoquinoline series Proc Am Assoc Cancer Res 2007. abstract</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Thayer SP, di Magliano MP,
     Heiser PW, Nielsen CM, Roberts DJ, Lauwers GY, Qi YP, Gysin S,
     Fernandez-del Castillo C, Yajnik V, Antoniu B, McMahon M, Warshaw AL,
     Hebrok M. Hedgehog is an early and late mediator of pancreatic cancer
     tumorigenesis. Nature. 2003;425:851856. [<a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3688051/">PMC free
     article</a>] [<a href="http://www.ncbi.nlm.nih.gov/pubmed/14520413"
     target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Vogt PK, Bader AG, Kang S.
     Phosphoinositide 3-kinase: from viral oncoprotein to drug target 3. Virology.
     2006;344:131138. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/16364744"
     target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Woodgett JR. Recent advances
     in the protein kinase B signaling pathway 5. Curr Opin Cell Biol. 2005;17:150157.
     [<a href="http://www.ncbi.nlm.nih.gov/pubmed/15780591" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Workman P, Clarke PA,
     Guillard S, Raynaud FI. Drugging the PI3 kinome 7. Nat Biotechnol. 2006;24:794796.
     [<a href="http://www.ncbi.nlm.nih.gov/pubmed/16841064" target="pmc_ext">PubMed</a>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Yau CY, Wheeler JJ, Sutton
     KL, Hedley DW. Inhibition of integrin-linked kinase by a selective small
     molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR
     pathways and tumor growth, and enhances gemcitabine-induced apoptosis in
     human orthotopic primary pancreatic cancer xenografts 1. Cancer Res. 2005;65:14971504.
     [<a href="http://www.ncbi.nlm.nih.gov/pubmed/15735038" target="pmc_ext">PubMed</a>]</span></li>
</ul>

<ul type=disc>
 <li class=MsoNormal style='line-height:normal;display:none'><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif";display:
     none'><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#__abstractid854327title">Abstract</a></span></li>
 <li class=MsoNormal style='line-height:normal;display:none'><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif";display:
     none'><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#__sec1title">Materials
     and methods</a></span></li>
 <li class=MsoNormal style='line-height:normal;display:none'><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif";display:
     none'><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#__sec8title">Results</a></span></li>
 <li class=MsoNormal style='line-height:normal;display:none'><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif";display:
     none'><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#__sec13title">Discussion</a></span></li>
 <li class=MsoNormal style='line-height:normal;display:none'><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif";display:
     none'><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#sup1title">Supplementary
     Material</a></span></li>
 <li class=MsoNormal style='line-height:normal;display:none'><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif";display:
     none'><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#__ackid827891title">Acknowledgments</a></span></li>
 <li class=MsoNormal style='line-height:normal;display:none'><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif";display:
     none'><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#__notesid827908title">Notes</a></span></li>
 <li class=MsoNormal style='line-height:normal;display:none'><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif";display:
     none'><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/#__ref-listid821318title">References</a></span></li>
</ul>

<div class=MsoNormal align=center style='margin-bottom:0in;margin-bottom:.0001pt;
text-align:center;line-height:normal'><span lang=EN style='font-size:12.0pt;
font-family:"Times New Roman","serif"'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal align=center style='margin-bottom:0in;margin-bottom:.0001pt;
text-align:center;line-height:normal'><span lang=EN style='font-size:12.0pt;
font-family:"Arial","sans-serif"'>Articles from British Journal of Cancer are
provided here courtesy of <b>Cancer Research UK</b></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/?report=reader"><span
style='font-size:12.0pt;font-family:"Times New Roman","serif";text-decoration:
none'><img border=0 width=240 height=59 id="Picture 4"
src="PMC2676548%20table%201_files/image012.png"
alt="PubReader format: click here to try"></span></a></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:18.0pt;font-family:"Times New Roman","serif"'>Formats:</span></b></p>

<ul type=disc>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Article</span></li>
</ul>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;line-height:normal'><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif"'>| </span></p>

<ul type=disc>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/?report=reader">PubReader</a></span></li>
</ul>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;line-height:normal'><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif"'>| </span></p>

<ul type=disc>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/epub/">ePub
     (beta)</a></span></li>
</ul>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;line-height:normal'><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif"'>| </span></p>

<ul type=disc>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/pdf/6604995a.pdf">PDF
     (487K)</a></span></li>
</ul>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;line-height:normal'><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif"'>| </span></p>

<ul type=disc>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/">Citation</a></span></li>
</ul>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:18.0pt;font-family:"Times New Roman","serif"'>Share</span></b></p>

<ul type=disc>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'><a
     href="https://www.facebook.com/sharer/sharer.php?u=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2676548%2F"
     target="_blank"><span lang=EN-US style='text-decoration:none'><img
     border=0 width=32 height=32 id="Picture 3"
     src="PMC2676548%20table%201_files/image013.png" alt="Share on Facebook"></span>Facebook
     </a></span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'><a
     href="https://twitter.com/intent/tweet?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2676548%2F&amp;text=Activity%20of%20a%20novel%2C%20dual%20PI3-kinase%2FmTor%20inhibitor%20NVP-BEZ235%20against%20primary%20human%20pancreatic%20cancers%20grown%20as%20orthotopic%20xenografts"
     target="_blank"><span lang=EN-US style='text-decoration:none'><img
     border=0 width=32 height=32 id="Picture 2"
     src="PMC2676548%20table%201_files/image014.png" alt="Share on Twitter"></span>Twitter
     </a></span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'><a
     href="https://plus.google.com/share?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2676548%2F"
     target="_blank"><span lang=EN-US style='text-decoration:none'><img
     border=0 width=32 height=32 id="Picture 1"
     src="PMC2676548%20table%201_files/image015.png" alt="Share on Google Plus"></span>Google+
     </a></span></li>
</ul>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Save items</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a name=Shutter><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><span
style='display:none'><INPUT TYPE="hidden" NAME="absid" VALUE="2676548"></span></span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal;background:#F6F6F6'><a
href="http://www.ncbi.nlm.nih.gov/myncbi/collections/"><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Add to Favorites</span></a><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/"
title="View more options"><span lang=EN style='font-size:12.0pt;font-family:
"Times New Roman","serif"'>View more options</span></a></p>

<ul type=disc>
 <li class=MsoNormal style='line-height:normal'><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/"><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Create
     collection...</span></a></li>
 <li class=MsoNormal style='line-height:normal'><a
     href="http://www.ncbi.nlm.nih.gov/myncbi/collections/"><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Manage
     collections...</span></a></li>
</ul>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>loading</span></p>

<div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>

<p class=MsoNormal align=center style='margin-bottom:0in;margin-bottom:.0001pt;
text-align:center;line-height:normal;border:none;padding:0in'><span
style='font-size:8.0pt;font-family:"Arial","sans-serif";display:none'>Top of
Form</span></p>

</div>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><INPUT TYPE="submit" VALUE="1" METHOD="post" NAME="addtocollection"></span></p>

<div style='border:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 0in 0in'>

<p class=MsoNormal align=center style='margin-bottom:0in;margin-bottom:.0001pt;
text-align:center;line-height:normal;border:none;padding:0in'><span
style='font-size:8.0pt;font-family:"Arial","sans-serif";display:none'>Bottom of
Form</span></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Similar articles
in PubMed</span></b></p>

<ul type=disc>
 <li class=MsoNormal style='line-height:normal'><a
     href="http://www.ncbi.nlm.nih.gov/pubmed/24100660"><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Efficacy of
     the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib
     against BCR-ABL-positive leukemia cells involves the ABL kinase domain
     mutation.</span></a><span lang=EN style='font-size:12.0pt;font-family:
     "Times New Roman","serif"'>[Cancer Biol Ther. 2014]</span></li>
</ul>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><i><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>Okabe S, Tauchi T, Tanaka Y, Kitahara T, Kimura S, Maekawa T,
Ohyashiki K. Cancer Biol Ther. 2014 Feb; 15(2):207-15. Epub 2013 Nov 8.</span></i><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'> </span></p>

<ul type=disc>
 <li class=MsoNormal style='line-height:normal'><a
     href="http://www.ncbi.nlm.nih.gov/pubmed/22020918"><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif"'>The
     efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance
     chemotherapy and antiangiogenic response in pancreatic cancer.</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>[J
     Cell Biochem. 2012]</span></li>
</ul>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><i><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>Awasthi N, Yen PL, Schwarz MA, Schwarz RE. J Cell Biochem. 2012
Mar; 113(3):784-91. </span></i></p>

<ul type=disc>
 <li class=MsoNormal style='line-height:normal'><a
     href="http://www.ncbi.nlm.nih.gov/pubmed/18606717"><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Identification
     and characterization of NVP-BEZ235, a new orally available dual
     phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with
     potent in vivo antitumor activity.</span></a><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif"'>[Mol Cancer
     Ther. 2008]</span></li>
</ul>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><i><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C,
Brachmann S, Chne P, De Pover A, Schoemaker K, et al. Mol Cancer Ther. 2008
Jul; 7(7):1851-63. Epub 2008 Jul 7.</span></i><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";display:none'> </span></p>

<ul type=disc>
 <li class=MsoNormal style='line-height:normal'><a
     href="http://www.ncbi.nlm.nih.gov/pubmed/23215722"><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Studies of
     NVP-BEZ235 in melanoma.</span></a><span lang=EN style='font-size:12.0pt;
     font-family:"Times New Roman","serif"'>[Curr Cancer Drug Targets. 2013]</span></li>
</ul>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><i><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>Sznol JA, Jilaveanu LB, Kluger HM. Curr Cancer Drug Targets. 2013
Feb; 13(2):165-74. </span></i></p>

<ul type=disc>
 <li class=MsoNormal style='line-height:normal'><a
     href="http://www.ncbi.nlm.nih.gov/pubmed/19644473"><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Targeting
     the phosphoinositide 3-kinase pathway in cancer.</span></a><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif"'>[Nat Rev
     Drug Discov. 2009]</span></li>
</ul>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><i><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>Liu P, Cheng H, Roberts TM, Zhao JJ. Nat Rev Drug Discov. 2009
Aug; 8(8):627-44. </span></i></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=19319133&amp;log%24=relatedreviews&amp;logdbfrom=pmc"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>See
reviews...</span></a><a
href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=19319133&amp;log%24=relatedarticles&amp;logdbfrom=pmc"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>See
all...</span></a></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Cited by other
articles in PMC</span></b></p>

<ul type=disc>
 <li class=MsoNormal style='line-height:normal'><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855228/"><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Neuroprotective
     effects of the anticancer drug NVP-BEZ235 (dactolisib) on amyloid-&#946;
     142 induced neurotoxicity and memory impairment</span></a><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif"'>[Scientific
     Reports. 2016]</span></li>
</ul>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><i><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>Bellozi PM, Lima IV, Dria JG, Vieira L, Campos AC,
Candelario-Jalil E, Reis HJ, Teixeira AL, Ribeiro FM, de Oliveira AC. Scientific
Reports. 2016 May 4; 625226</span></i><span lang=EN style='font-size:12.0pt;
font-family:"Times New Roman","serif";display:none'> </span></p>

<ul type=disc>
 <li class=MsoNormal style='line-height:normal'><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782390/"><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PI3K/AKT/mTOR
     inhibition in combination with doxorubicin is an effective therapy for
     leiomyosarcoma</span></a><span lang=EN style='font-size:12.0pt;font-family:
     "Times New Roman","serif"'>[Journal of Translational Medic...]</span></li>
</ul>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><i><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>Babichev Y, Kabaroff L, Datti A, Uehling D, Isaac M, Al-awar R,
Prakesch M, Sun RX, Boutros PC, Venier R, Dickson BC, Gladdy RA. Journal of
Translational Medicine. 2016 Mar 8; 1467</span></i><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif";display:none'> </span></p>

<ul type=disc>
 <li class=MsoNormal style='line-height:normal'><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695016/"><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Crocetinic
     acid inhibits hedgehog signaling to inhibit pancreatic cancer stem cells</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>[Oncotarget.
     2015]</span></li>
</ul>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><i><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>Rangarajan P, Subramaniam D, Paul S, Kwatra D, Palaniyandi K,
Islam S, Harihar S, Ramalingam S, Gutheil W, Putty S, Pradhan R, Padhye S,
Welch DR, Anant S, Dhar A. Oncotarget. 2015 Aug 13; 6(29)27661-27673</span></i><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'> </span></p>

<ul type=disc>
 <li class=MsoNormal style='line-height:normal'><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641417/"><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Dual
     PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in
     HER2-positive gastric cancer</span></a><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>[BMC Cancer. 2015]</span></li>
</ul>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><i><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>Zhu Y, Tian T, Zou J, Wang Q, Li Z, Li Y, Liu X, Dong B, Li N,
Gao J, Shen L. BMC Cancer. 2015 Nov 11; 15894</span></i><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif";display:none'> </span></p>

<ul type=disc>
 <li class=MsoNormal style='line-height:normal'><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4442711/"><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif"'>P85&#945;
     is a miR target and affects chemosensitivity in pancreatic cancer</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>[The
     Journal of surgical resear...]</span></li>
</ul>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><i><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>Toste PA, Li L, Kadera BE, Nguyen AH, Tran LM, Wu N, Madnick DL,
Patel SG, Dawson DW, Donahue TR. The Journal of surgical research. 2015 Mar 6;
196(2)285-293</span></i><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'> </span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/citedby/"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>See
all...</span></a></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Links</span></b></p>

<ul type=disc>
 <li class=MsoNormal style='line-height:normal'><a
     href="http://www.ncbi.nlm.nih.gov/pmc/?Db=pccompound&amp;DbFrom=pmc&amp;Cmd=Link&amp;LinkName=pmc_pccompound&amp;IdsFromResult=2676548"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Compound</span></a></li>
</ul>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif";display:none'>Compound</span></p>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><span lang=EN
style='font-size:10.0pt;font-family:"Times New Roman","serif";display:none'>PubChem
Compound links</span></p>

<ul type=disc>
 <li class=MsoNormal style='line-height:normal'><a
     href="http://www.ncbi.nlm.nih.gov/pmc/?Db=medgen&amp;DbFrom=pmc&amp;Cmd=Link&amp;LinkName=pmc_medgen&amp;IdsFromResult=2676548"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>MedGen</span></a></li>
</ul>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif";display:none'>MedGen</span></p>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><span lang=EN
style='font-size:10.0pt;font-family:"Times New Roman","serif";display:none'>Related
information in MedGen</span></p>

<ul type=disc>
 <li class=MsoNormal style='line-height:normal'><a
     href="http://www.ncbi.nlm.nih.gov/pubmed/19319133/"><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PubMed</span></a></li>
</ul>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif";display:none'>PubMed</span></p>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><span lang=EN
style='font-size:10.0pt;font-family:"Times New Roman","serif";display:none'>PubMed
citations for these articles</span></p>

<ul type=disc>
 <li class=MsoNormal style='line-height:normal'><a
     href="http://www.ncbi.nlm.nih.gov/pmc/?Db=pcsubstance&amp;DbFrom=pmc&amp;Cmd=Link&amp;LinkName=pmc_pcsubstance&amp;IdsFromResult=2676548"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Substance</span></a></li>
</ul>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif";display:none'>Substance</span></p>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><span lang=EN
style='font-size:10.0pt;font-family:"Times New Roman","serif";display:none'>PubChem
Substance links</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Recent Activity</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="javascript:historyDisplayState('ClearHT')">Clear</a><a
href="javascript:historyDisplayState('HTOff')">Turn Off</a><a
href="javascript:historyDisplayState('HTOn')">Turn On</a> </span></p>

<ul type=disc>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'><a
     href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576bf18f04fcfad5916c97ea">Activity
     of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary h...</a></span></li>
</ul>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Activity of a
novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human
pancreatic cancers grown as orthotopic xenografts</span></p>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><span lang=EN
style='font-size:10.0pt;font-family:"Times New Roman","serif"'>British Journal
of Cancer. 2009 Apr 14; 100(8)1267</span></p>

<ul type=disc>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'><a
     href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576aeae8faadcccd7d77385f">Reduction
     of serum IGF-I levels in patients affected with Monoclonal Gammopathie...</a></span></li>
</ul>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Reduction of
serum IGF-I levels in patients affected with Monoclonal Gammopathies of
undetermined significance or Multiple Myeloma. Comparison with bFGF, VEGF and
K-ras gene mutation</span></p>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><span lang=EN
style='font-size:10.0pt;font-family:"Times New Roman","serif"'>Journal of
Experimental &amp;#x0026; Clinical Cancer Research : CR. 2009; 28(1)35</span></p>

<ul type=disc>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'><a
     href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576ae8cffaadcccd7d76df0c">LKB1/KRAS
     mutant lung cancers constitute a genetic subset of NSCLC with increase...</a></span></li>
</ul>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif"'>LKB1/KRAS mutant
lung cancers constitute a genetic subset of NSCLC with increased sensitivity to
MAPK and mTOR signalling inhibition</span></p>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><span lang=EN
style='font-size:10.0pt;font-family:"Times New Roman","serif"'>British Journal
of Cancer. 2009 Jan 27; 100(2)370</span></p>

<ul type=disc>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'><a
     href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576ae5d6fb162bcc410705ee">KRAS
     or BRAF mutation status is a useful predictor of sensitivity to MEK
     inhibit...</a></span></li>
</ul>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif"'>KRAS or BRAF
mutation status is a useful predictor of sensitivity to MEK inhibition in
ovarian cancer</span></p>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><span lang=EN
style='font-size:10.0pt;font-family:"Times New Roman","serif"'>British Journal
of Cancer. 2008 Dec 9; 99(12)2020</span></p>

<ul type=disc>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'><a
     href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=57697034c6300fc52bb6ca7c">Somatic
     versus germinal mutation - An Introduction to Genetic Analysis</a></span></li>
</ul>

<p class=MsoNormal style='margin-left:.5in;line-height:normal'><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Somatic versus
germinal mutation - An Introduction to Genetic Analysis</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Your browsing activity is empty.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Activity recording is turned off.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'><a
href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/sites/myncbi/recentactivity">See more...</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><script  src="http://www.ncbi.nlm.nih.gov/corehtml/pmc/js/jquery.scrollTo-1.4.2.js">
</script><script>
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>You are here: <a href="http://www.ncbi.nlm.nih.gov/guide/">NCBI</a>
&gt; <a href="http://www.ncbi.nlm.nih.gov/guide/literature/">Literature</a>
&gt; <a href="http://www.ncbi.nlm.nih.gov/pmc/">PubMed Central (PMC)</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/sites/ehelp?&amp;Ncbi_App=pmc&amp;Db=pmc&amp;Page=literature&amp;Snapshot=/projects/PMC/PMCViewer@4.35&amp;Time=2016-06-23T10:26:23-04:00&amp;Host=ptpmc201"
target="_blank">Write to the Help Desk</a> </span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN style='font-size:18.0pt;font-family:"Times New Roman","serif"'>Simple
NCBI Directory</span></b></p>

<p class=MsoNormal>&nbsp;</p>

</div>

</body>

</html>
